IDEAS home Printed from https://ideas.repec.org/e/c/ppa171.html
   My authors  Follow this author

David Parkin

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Blog mentions

As found by EconAcademics.org, the blog aggregator for Economics research:
  1. Appleby, John & Devlin, Nancy & Parkin, David & Buxton, Martin & Chalkidou, Kalipso, 2009. "Searching for cost effectiveness thresholds in the NHS," Health Policy, Elsevier, vol. 91(3), pages 239-245, August.

    Mentioned in:

    1. Sofosbuvir: a fork in the road for NICE?
      by Chris Sampson in The Academic Health Economists' Blog on 2015-01-20 17:21:00

Working papers

  1. Helen Dakin & Nancy Devlin & Yan Feng & Nigel Rice & Phill O’Neill & David Parkin, 2013. "The influence of cost-effectiveness and other factors on NICE decisions," Working Papers 093cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Wettstein, Dominik J. & Boes, Stefan, 2022. "How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence," Health Policy, Elsevier, vol. 126(2), pages 112-121.
    2. Mikael Svensson & Fredrik Nilsson & Karl Arnberg, 2015. "Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness," PharmacoEconomics, Springer, vol. 33(11), pages 1229-1236, November.
    3. Maynou, Laia & Cairns, John, 2018. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," LSE Research Online Documents on Economics 90877, London School of Economics and Political Science, LSE Library.
    4. Lisa Masucci & Jaclyn Beca & Mona Sabharwal & Jeffrey S. Hoch, 2017. "Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)," PharmacoEconomics - Open, Springer, vol. 1(4), pages 255-263, December.
    5. Peter Ghijben & Yuanyuan Gu & Emily Lancsar & Silva Zavarsek, 2018. "Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review," PharmacoEconomics, Springer, vol. 36(3), pages 323-340, March.
    6. Olina Efthymiadou, 2023. "Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(7), pages 1023-1031, September.
    7. Maynou, Laia & Cairns, John, 2019. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," Health Policy, Elsevier, vol. 123(2), pages 130-139.
    8. Benedikt Schoser & Andreas Hahn & Emma James & Digant Gupta & Matthew Gitlin & Suyash Prasad, 2019. "A Systematic Review of the Health Economics of Pompe Disease," PharmacoEconomics - Open, Springer, vol. 3(4), pages 479-493, December.
    9. Jobjörnsson, Sebastian & Forster, Martin & Pertile, Paolo & Burman, Carl-Fredrik, 2016. "Late-stage pharmaceutical R&D and pricing policies under two-stage regulation," Journal of Health Economics, Elsevier, vol. 50(C), pages 298-311.
    10. J. Raftery, 2014. "NICE’s Cost-Effectiveness Range: Should it be Lowered?," PharmacoEconomics, Springer, vol. 32(7), pages 613-615, July.
    11. Carlos K. H. Wong & Brian H. H. Lang & Vivian Y. W. Guo & Cindy L. K. Lam, 2016. "Possible Impact of Incremental Cost-Effectiveness Ratio (ICER) on Decision Making for Cancer Screening in Hong Kong: A Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 14(6), pages 647-657, December.
    12. Shafrin, Jason & Skornicki, Michelle & Brauer, Michelle & Villeneuve, Julie & Lees, Michael & Hertel, Nadine & Penrod, John R. & Jansen, Jeroen, 2018. "An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?," Health Policy, Elsevier, vol. 122(6), pages 607-613.
    13. Pieter Baal & Alec Morton & David Meltzer & Werner Brouwer, 2019. "Future unrelated medical costs need to be considered in cost effectiveness analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 1-5, February.
    14. Francesco Paolucci & Ken Redekop & Ayman Fouda & Gianluca Fiorentini, 2017. "Decision Making and Priority Setting: The Evolving Path Towards Universal Health Coverage," Applied Health Economics and Health Policy, Springer, vol. 15(6), pages 697-706, December.
    15. Anna Hobbins & Luke Barry & Dan Kelleher & Koonal Shah & Nancy Devlin & Juan Manuel Ramos Goni & Ciaran O’Neill, 2018. "Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L," PharmacoEconomics, Springer, vol. 36(11), pages 1345-1353, November.
    16. Fischer, Katharina Elisabeth & Heisser, Thomas & Stargardt, Tom, 2016. "Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia," Health Policy, Elsevier, vol. 120(10), pages 1115-1122.
    17. M. J. Walton & J. O’Connor & C. Carroll & L. Claxton & R. Hodgson, 2019. "A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process," PharmacoEconomics - Open, Springer, vol. 3(3), pages 403-410, September.
    18. Carlos King Ho Wong & Olivia Wu & Bernard M. Y. Cheung, 2018. "Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions," Applied Health Economics and Health Policy, Springer, vol. 16(1), pages 5-14, February.
    19. Cynthia P. Iglesias & Alexander Thompson & Wolf H. Rogowski & Katherine Payne, 2016. "Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations," PharmacoEconomics, Springer, vol. 34(11), pages 1161-1172, November.
    20. Shiroiwa, Takeru & Fukuda, Takashi & Ikeda, Shunya & Takura, Tomoyuki, 2017. "New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations," Health Policy, Elsevier, vol. 121(8), pages 836-841.
    21. Angela Rocchi & Elizabeth Miller & Robert Hopkins & Ron Goeree, 2012. "Common Drug Review Recommendations," PharmacoEconomics, Springer, vol. 30(3), pages 229-246, March.
    22. Kerr, Anne & Hill, Rosemary L. & Till, Christopher, 2018. "The limits of responsible innovation: Exploring care, vulnerability and precision medicine," Technology in Society, Elsevier, vol. 52(C), pages 24-31.

  2. Nils Gutacker & Chris Bojke & Silvio Daidone & Nancy Devlin & David Parkin & Andrew Street, 2011. "Truly inefficient or providing better quality of care? Analysing the relationship between riskadjusted hospital costs and patients’ health outcomes," Working Papers 068cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Edwin Lau & Zsuzsanna Lonti & Rebecca Schultz, 2017. "Challenges in the Measurement of Public Sector Productivity in OECD 180 Countries," International Productivity Monitor, Centre for the Study of Living Standards, vol. 32, pages 180-195, Spring.
    2. Häkkinen, Unto & Rosenqvist, Gunnar & Peltola, Mikko & Kapiainen, Satu & Rättö, Hanna & Cots, Francesc & Geissler, Alexander & Or, Zeynep & Serdén, Lisbeth & Sund, Reijo, 2014. "Quality, cost, and their trade-off in treating AMI and stroke patients in European hospitals," Health Policy, Elsevier, vol. 117(1), pages 15-27.
    3. Francesco Longo & Luigi Siciliani & Andrew Street, 2019. "Are cost differences between specialist and general hospitals compensated by the prospective payment system?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 7-26, February.
    4. Steenhuis, Sander & Groeneweg, Niels & Koolman, Xander & Portrait, France, 2017. "Good, better, best? A comprehensive comparison of healthcare providers’ performance: An application to physiotherapy practices in primary care," Health Policy, Elsevier, vol. 121(12), pages 1225-1232.
    5. Smith, Andrew S.J. & Ojeda Cabral, Manuel, 2022. "Is higher quality always costly? Marginal costs of quality: Theory and application to railway punctuality," Transportation Research Part A: Policy and Practice, Elsevier, vol. 157(C), pages 258-273.
    6. Francesco Longo & Luigi Siciliani & Hugh Gravelle & Rita Santos, 2017. "Do hospitals respond to rivals' quality and efficiency? A spatial panel econometric analysis," Health Economics, John Wiley & Sons, Ltd., vol. 26(S2), pages 38-62, September.
    7. Valerie Moran & Rowena Jacobs, 2018. "Investigating the relationship between costs and outcomes for English mental health providers: a bi-variate multi-level regression analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(5), pages 709-718, June.
    8. Laura Di Giorgio & Massimo Filippini & Giuliano Masiero, 2014. "The relationship between costs and quality in nonprofit nursing homes," IdEP Economic Papers 1402, USI Università della Svizzera italiana.
    9. Adrian Gheorghe & Tracy Roberts & Karla Hemming & Melanie Calvert, 2015. "Evaluating the Generalisability of Trial Results: Introducing a Centre- and Trial-Level Generalisability Index," PharmacoEconomics, Springer, vol. 33(11), pages 1195-1214, November.
    10. France R. M. Portrait & Onno van der Galiën & Bernard Van den Berg, 2016. "Measuring Healthcare Providers' Performances Within Managed Competition Using Multidimensional Quality and Cost Indicators," Health Economics, John Wiley & Sons, Ltd., vol. 25(4), pages 408-423, April.
    11. Enrique Jiménez-Rodríguez & José Manuel Feria-Domínguez & Alonso Sebastián-Lacave, 2018. "Assessing the Health-Care Risk: The Clinical-VaR, a Key Indicator for Sound Management," IJERPH, MDPI, vol. 15(4), pages 1-17, March.
    12. L. Di Giorgio & M. Filippini & G. Masiero, 2016. "Is higher nursing home quality more costly?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 1011-1026, November.
    13. Tor Iversen & Eline Aas & Gunnar Rosenqvist & Unto Häkkinen & on behalf of the EuroHOPE study group, 2015. "Comparative Analysis of Treatment Costs in EUROHOPE," Health Economics, John Wiley & Sons, Ltd., vol. 24(S2), pages 5-22, December.
    14. J. Buckell & A. Smith & R. Longo & D. Holland, 2015. "Efficiency, heterogeneity and cost function analysis: empirical evidence from pathology services in the National Health Service in England," Applied Economics, Taylor & Francis Journals, vol. 47(31), pages 3311-3331, July.
    15. Francette Koechlin & Paul Konijn & Luca Lorenzoni & Paul Schreyer, 2017. "Comparing Hospitals and Health Prices and Volumes Across Countries: A New Approach," Social Indicators Research: An International and Interdisciplinary Journal for Quality-of-Life Measurement, Springer, vol. 131(1), pages 43-64, March.
    16. Malgorzata Cyganska & Piotr Cyganski & Chris Pyke, 2019. "Development of clinical value unit method for calculating patient costs," Health Economics, John Wiley & Sons, Ltd., vol. 28(8), pages 971-983, August.
    17. Sverre A. C. Kittelsen & Kjartan S. Anthun & Fanny Goude & Ingrid M. S. Huitfeldt & Unto Häkkinen & Marie Kruse & Emma Medin & Clas Rehnberg & Hanna Rättö & on behalf of the EuroHOPE study group, 2015. "Costs and Quality at the Hospital Level in the Nordic Countries," Health Economics, John Wiley & Sons, Ltd., vol. 24(S2), pages 140-163, December.
    18. Sara Jamalabadi & Vera Winter & Jonas Schreyögg, 2020. "A Systematic Review of the Association Between Hospital Cost/price and the Quality of Care," Applied Health Economics and Health Policy, Springer, vol. 18(5), pages 625-639, October.
    19. Unto Häkkinen & Gunnar Rosenqvist & Tor Iversen & Clas Rehnberg & Timo T. Seppälä & on behalf of the EuroHOPE study group, 2015. "Outcome, Use of Resources and Their Relationship in the Treatment of AMI, Stroke and Hip Fracture at European Hospitals," Health Economics, John Wiley & Sons, Ltd., vol. 24(S2), pages 116-139, December.
    20. Seghieri, Chiara & Berta, Paolo & Nuti, Sabina, 2019. "Geographic variation in inpatient costs for Acute Myocardial Infarction care: Insights from Italy," Health Policy, Elsevier, vol. 123(5), pages 449-456.

  3. Devlin, N. & Parkin, D. & Browne, J., 2009. "Using the EQ-5D as a performance measurement tool in the NHS," Working Papers 09/03, Department of Economics, City University London.

    Cited by:

    1. Weale, Martin, 2011. "A cost-benefit analysis of cataract surgery based on the English Longitudinal Survey of Ageing," Journal of Health Economics, Elsevier, vol. 30(4), pages 730-739, July.
    2. A. Enrique & J. Burke & D. Richards & L. Timulak, 2019. "Quality of Life Outcomes in Internet-Delivered (Space from Depression) Treatment for Depression," Applied Research in Quality of Life, Springer;International Society for Quality-of-Life Studies, vol. 14(5), pages 1301-1313, November.

  4. Parkin, D. & Rice, N. & Devlin, N., 2008. "Statistical analysis of EQ-5D profiles: does the use of value sets bias inference?," Working Papers 08/10, Department of Economics, City University London.

    Cited by:

    1. Jeff Round & Annie Hawton, 2017. "Statistical Alchemy: Conceptual Validity and Mapping to Generate Health State Utility Values," PharmacoEconomics - Open, Springer, vol. 1(4), pages 233-239, December.
    2. Raymond Oppong & Billingsley Kaambwa & Jacqueline Nuttall & Kerenza Hood & Richard Smith & Joanna Coast, 2013. "The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(2), pages 197-209, April.
    3. Franz Ombler & Michael Albert & Paul Hansen, 2018. "How Significant Are “High†Correlations Between EQ-5D Value Sets?," Medical Decision Making, , vol. 38(6), pages 635-645, August.
    4. Manuel B. Huber & Julia Felix & Martin Vogelmann & Reiner Leidl, 2017. "Health-Related Quality of Life of the General German Population in 2015: Results from the EQ-5D-5L," IJERPH, MDPI, vol. 14(4), pages 1-12, April.
    5. McCarthy, Ian M., 2016. "Eliminating composite bias in treatment effects estimates: Applications to quality of life assessment," Journal of Health Economics, Elsevier, vol. 50(C), pages 47-58.
    6. A. Enrique & J. Burke & D. Richards & L. Timulak, 2019. "Quality of Life Outcomes in Internet-Delivered (Space from Depression) Treatment for Depression," Applied Research in Quality of Life, Springer;International Society for Quality-of-Life Studies, vol. 14(5), pages 1301-1313, November.
    7. Tianxin Pan & Brendan Mulhern & Rosalie Viney & Richard Norman & Janel Hanmer & Nancy Devlin, 2022. "A Comparison of PROPr and EQ-5D-5L Value Sets," PharmacoEconomics, Springer, vol. 40(3), pages 297-307, March.
    8. Caitlyn T. Wilke & A. Simon Pickard & Surrey M. Walton & Joern Moock & Thomas Kohlmann & Todd A. Lee, 2010. "Statistical implications of utility weighted and equally weighted HRQL measures: an empirical study," Health Economics, John Wiley & Sons, Ltd., vol. 19(1), pages 101-110, January.
    9. Xiaojing Fan & Duolao Wang & Bruce Hellman & Mathieu F. Janssen & Gerben Bakker & Rupert Coghlan & Amelia Hursey & Helen Matthews & Ian Whetstone, 2018. "Assessment of Health-Related Quality of Life between People with Parkinson’s Disease and Non-Parkinson’s: Using Data Drawn from the ‘100 for Parkinson’s’ Smartphone-Based Prospective Study," IJERPH, MDPI, vol. 15(11), pages 1-12, November.

  5. Sadique, Z. & Edmunds, W. J. & Devlin, N. & Parkin, D., 2005. "Understanding individuals’ decisions about vaccination: a comparison between Expected Utility and Regret Theory models," Working Papers 05/03, Department of Economics, City University London.

    Cited by:

    1. Kairiza, Terrence & Kembo, George & Chigusiwa, Lloyd, 2023. "Herding behavior in COVID-19 vaccine hesitancy in rural Zimbabwe: The moderating role of health information under heterogeneous household risk perceptions," Social Science & Medicine, Elsevier, vol. 323(C).

  6. Parkin, D. & Devlin, N., 2004. "Is there a case for using Visual Analogue Scale valuations in Cost-Utility Analysis?," Working Papers 04/03, Department of Economics, City University London.

    Cited by:

    1. Hildegard Seidl & Matthias Hunger & Reiner Leidl & Christa Meisinger & Rupert Wende & Bernhard Kuch & Rolf Holle, 2015. "Cost-effectiveness of nurse-based case management versus usual care for elderly patients with myocardial infarction: results from the KORINNA study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(6), pages 671-681, July.
    2. Mara Airoldi & Alec Morton & Jenifer A. E. Smith & Gwyn Bevan, 2014. "STAR—People-Powered Prioritization," Medical Decision Making, , vol. 34(8), pages 965-975, November.
    3. Keith Tolley & Catherine Goad & Yunni Yi & Penny Maroudas & Amin Haiderali & Gwilym Thompson, 2013. "Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(5), pages 749-759, October.
    4. Ryan, Mandy & Kinghorn, Philip & Entwistle, Vikki A. & Francis, Jill J., 2014. "Valuing patients' experiences of healthcare processes: Towards broader applications of existing methods," Social Science & Medicine, Elsevier, vol. 106(C), pages 194-203.
    5. Khadka, Jyoti & Kwon, Joseph & Petrou, Stavros & Lancsar, Emily & Ratcliffe, Julie, 2019. "Mind the (inter-rater) gap. An investigation of self-reported versus proxy-reported assessments in the derivation of childhood utility values for economic evaluation: A systematic review," Social Science & Medicine, Elsevier, vol. 240(C).
    6. Joseph Kwon & Sung Wook Kim & Wendy J. Ungar & Kate Tsiplova & Jason Madan & Stavros Petrou, 2018. "A Systematic Review and Meta-analysis of Childhood Health Utilities," Medical Decision Making, , vol. 38(3), pages 277-305, April.
    7. Buckingham, K. & Devlin, N. & Tabberer, M., 2004. "A theoretical framework for TTO valuations and a taxonomy of TTO approaches: results from a pilot study," Working Papers 04/07, Department of Economics, City University London.
    8. Koonal K. Shah & Juan Manuel Ramos-Goñi & Simone Kreimeier & Nancy J. Devlin, 2020. "An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(7), pages 1091-1103, September.
    9. Shaofan Chen & Bo Burström & Vibeke Sparring & Dongfu Qian & Kristina Burström, 2019. "Differential Impact of an Education-Based Intervention for Patients with Type 2 Diabetes Mellitus in Rural China," IJERPH, MDPI, vol. 16(15), pages 1-12, July.
    10. Jeff Richardson & Angelo Iezzi & Kompal Sinha & Munir A. Khan & John Mckie, 2014. "An Instrument For Measuring The Social Willingness To Pay For Health State Improvement," Health Economics, John Wiley & Sons, Ltd., vol. 23(7), pages 792-805, July.
    11. Buckingham, Ken J. & Devlin, Nancy Joy, 2009. "A note on the nature of utility in time and health and implications for cost utility analysis," Social Science & Medicine, Elsevier, vol. 68(2), pages 362-367, January.
    12. Arthur E. Attema & Werner B.F. Brouwer, 2014. "Deriving Time Discounting Correction Factors For Tto Tariffs," Health Economics, John Wiley & Sons, Ltd., vol. 23(4), pages 410-425, April.
    13. J. Shannon Swan & Chung Yin Kong & Janie M. Lee & Omosalewa Itauma & Elkan F. Halpern & Pablo A. Lee & Sergey Vavinskiy & Olubunmi Williams & Emilie S. Zoltick & Karen Donelan, 2013. "Patient and Societal Value Functions for the Testing Morbidities Index," Medical Decision Making, , vol. 33(6), pages 819-838, August.
    14. Christine McDonough & Anna Tosteson, 2007. "Measuring Preferences for Cost-Utility Analysis," PharmacoEconomics, Springer, vol. 25(2), pages 93-106, February.
    15. George L. Wehby & Hodad Naderi & James M. Robbins & Timothy N. Ansley & Peter C. Damiano, 2014. "Comparing the Visual Analogue Scale and the Pediatric Quality of Life Inventory for Measuring Health-Related Quality of Life in Children with Oral Clefts," IJERPH, MDPI, vol. 11(4), pages 1-12, April.
    16. Dirk Müller & Marion Danner & Kerstin Rhiem & Björn Stollenwerk & Christoph Engel & Linda Rasche & Lisa Borsi & Rita Schmutzler & Stephanie Stock, 2018. "Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(3), pages 341-353, April.
    17. Hirsch Ruchlin & Ralph Insinga, 2008. "A Review of Health-Utility Data for Osteoarthritis," PharmacoEconomics, Springer, vol. 26(11), pages 925-935, November.
    18. Irvine, Alastair & van der Pol, Marjon & Phimister, Euan, 2019. "A comparison of professional and private time preferences of General Practitioners," Social Science & Medicine, Elsevier, vol. 222(C), pages 256-264.
    19. Huynh, Elisabeth & Coast, Joanna & Rose, John & Kinghorn, Philip & Flynn, Terry, 2017. "Values for the ICECAP-Supportive Care Measure (ICECAP-SCM) for use in economic evaluation at end of life," Social Science & Medicine, Elsevier, vol. 189(C), pages 114-128.
    20. Stavros Petrou & Joseph Kwon & Jason Madan, 2018. "A Practical Guide to Conducting a Systematic Review and Meta-analysis of Health State Utility Values," PharmacoEconomics, Springer, vol. 36(9), pages 1043-1061, September.
    21. Daniel M. Hausman, 2010. "Valuing health: a new proposal," Health Economics, John Wiley & Sons, Ltd., vol. 19(3), pages 280-296, March.
    22. Kyra Kneis & Afschin Gandjour, 2009. "Economic evaluation of Sinfrontal®in the treatment of acute maxillary sinusitis in adults," Applied Health Economics and Health Policy, Springer, vol. 7(3), pages 181-191, September.
    23. Donna Rowen & Oliver Rivero-Arias & Nancy Devlin & Julie Ratcliffe, 2020. "Review of Valuation Methods of Preference-Based Measures of Health for Economic Evaluation in Child and Adolescent Populations: Where are We Now and Where are We Going?," PharmacoEconomics, Springer, vol. 38(4), pages 325-340, April.
    24. Zsombor Zrubka & Zoltán Hermann & László Gulácsi & Valentin Brodszky & Fanni Rencz & Márta Péntek, 2019. "Determinants of the acceptability of health problems in different ages: exploring a new application of the EQ VAS," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 31-41, June.
    25. Mimmi Åström & Ola Rolfson & Kristina Burström, 2022. "Exploring EQ-5D-Y-3L Experience-Based VAS Values Derived Among Adolescents," Applied Health Economics and Health Policy, Springer, vol. 20(3), pages 383-393, May.
    26. Nancy Devlin & Paul Hansen & Peter Herbison & Susan Macran, 2005. "A ‘new and improved’ EQ-5D valuation questionnaire?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(1), pages 73-82, March.
    27. Bobinac, Ana & van Exel, N. Job A. & Rutten, Frans F.H. & Brouwer, Werner B.F., 2012. "GET MORE, PAY MORE? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation," Journal of Health Economics, Elsevier, vol. 31(1), pages 158-168.
    28. Arthur E. Attema & Marieke Krol & Job Exel & Werner B. F. Brouwer, 2018. "New findings from the time trade-off for income approach to elicit willingness to pay for a quality adjusted life year," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(2), pages 277-291, March.
    29. Nancy J. Devlin & Koonal K. Shah & Brendan J. Mulhern & Krystallia Pantiri & Ben van Hout, 2019. "A new method for valuing health: directly eliciting personal utility functions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(2), pages 257-270, March.
    30. Edward J. D. Webb & John O’Dwyer & David Meads & Paul Kind & Penny Wright, 2020. "Transforming discrete choice experiment latent scale values for EQ-5D-3L using the visual analogue scale," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(5), pages 787-800, July.
    31. Nord, Erik, 2012. "Measuring concerns for severity: Re-examination of a health scale with purported equal interval properties," Health Policy, Elsevier, vol. 105(2), pages 312-316.
    32. van den Berg, Bernard & Van Dommelen, Paula & Stam, Piet & Laske-Aldershof, Trea & Buchmueller, Tom & Schut, Frederik T., 2008. "Preferences and choices for care and health insurance," Social Science & Medicine, Elsevier, vol. 66(12), pages 2448-2459, June.

  7. Tsuchiya, A & Brazier, J & McColl, E & Parkin, D, 2002. "Deriving preference-based single indices from non-preference based condition-specific instruments: converting AQLQ into EQ5D indices," MPRA Paper 29740, University Library of Munich, Germany.

    Cited by:

    1. Jeff Round & Annie Hawton, 2017. "Statistical Alchemy: Conceptual Validity and Mapping to Generate Health State Utility Values," PharmacoEconomics - Open, Springer, vol. 1(4), pages 233-239, December.
    2. Brazier, JE & Yang, Y & Tsuchiya, A, 2008. "A review of studies mapping (or cross walking) from non-preference based measures of health to generic preference-based measures," MPRA Paper 29808, University Library of Munich, Germany.
    3. Jihyung Hong & Eun-Young Bae, 2021. "A Review of Utility Measurement Methods Used in Pharmacoeconomic Submissions to HIRA in South Korea: Methodological Consistency and Areas for Improvement," PharmacoEconomics, Springer, vol. 39(10), pages 1109-1121, October.
    4. Zafar Zafari & Mohsen Sadatsafavi & Carlo A Marra & Wenjia Chen & J Mark FitzGerald, 2016. "Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma," PLOS ONE, Public Library of Science, vol. 11(1), pages 1-15, January.
    5. Kamran Khan & Stavros Petrou & Oliver Rivero-Arias & Stephen Walters & Spencer Boyle, 2014. "Mapping EQ-5D Utility Scores from the PedsQL™ Generic Core Scales," PharmacoEconomics, Springer, vol. 32(7), pages 693-706, July.
    6. Samer A. Kharroubi & Richard Edlin & David Meads & Chantelle Browne & Julia Brown & Christopher McCabe, 2015. "Use of Bayesian Markov Chain Monte Carlo Methods to Estimate EQ-5D Utility Scores from EORTC QLQ Data in Myeloma for Use in Cost-Effectiveness Analysis," Medical Decision Making, , vol. 35(3), pages 351-360, April.
    7. Rowen, D & Brazier, J & Tsuchiya, A & Hernández, M & Ibbotson, R, 2009. "The simultaneous valuation of states from multiple instruments using ranking and VAS data: methods and preliminary results," MPRA Paper 29841, University Library of Munich, Germany.
    8. John Brazier & Yaling Yang & Aki Tsuchiya & Donna Rowen, 2010. "A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(2), pages 215-225, April.
    9. Billingsley Kaambwa & Julie Ratcliffe, 2018. "Predicting EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Utilities from Older People’s Quality of Life Brief Questionnaire (OPQoL-Brief) Scores," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 11(1), pages 39-54, February.
    10. Matthijs M. Versteegh & Annemieke Leunis & Jolanda J. Luime & Mike Boggild & Carin A. Uyl-de Groot & Elly A. Stolk, 2012. "Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D," Medical Decision Making, , vol. 32(4), pages 554-568, July.
    11. Yaling Yang & John E. Brazier & Aki Tsuchiya & Tracey A. Young, 2011. "Estimating a Preference-Based Index for a 5-Dimensional Health State Classification for Asthma Derived from the Asthma Quality of Life Questionnaire," Medical Decision Making, , vol. 31(2), pages 281-291, March.
    12. Matthew Franklin & Katherine Payne & Rachel A. Elliott, 2018. "Quantifying the Relationship between Capability and Health in Older People: Can’t Map, Won’t Map," Medical Decision Making, , vol. 38(1), pages 79-94, January.
    13. Billingsley Kaambwa & Gang Chen & Julie Ratcliffe & Angelo Iezzi & Aimee Maxwell & Jeff Richardson, 2017. "Mapping Between the Sydney Asthma Quality of Life Questionnaire (AQLQ-S) and Five Multi-Attribute Utility Instruments (MAUIs)," PharmacoEconomics, Springer, vol. 35(1), pages 111-124, January.
    14. Nick Kontodimopoulos & Panagiotis Bozios & John Yfantopoulos & Dimitris Niakas, 2013. "Longitudinal predictive ability of mapping models: examining post-intervention EQ-5D utilities derived from baseline MHAQ data in rheumatoid arthritis patients," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(2), pages 307-314, April.
    15. Donna Rowen & John Brazier & Aki Tsuchiya & Mónica Hernández Alava, 2012. "Valuing states from multiple measures on the same visual analogue sale: a feasibility study," Health Economics, John Wiley & Sons, Ltd., vol. 21(6), pages 715-729, June.
    16. Christine Mpundu-Kaambwa & Gang Chen & Remo Russo & Katherine Stevens & Karin Dam Petersen & Julie Ratcliffe, 2017. "Mapping CHU9D Utility Scores from the PedsQLTM 4.0 SF-15," PharmacoEconomics, Springer, vol. 35(4), pages 453-467, April.

  8. Kobelt, Gisela & Lindgren, Peter & Parkin, David & Francis, David A. & Johnson, Michael & Bates, David & Jönsson, Bengt, 2000. "Costs and Quality of Life in Multiple Sclerosis. A Cross-Sectional Observational Study in the UK," SSE/EFI Working Paper Series in Economics and Finance 398, Stockholm School of Economics.

    Cited by:

    1. Jenny Berg & P. Lindgren & Sten Fredrikson & Gisela Kobelt, 2006. "Costs and quality of life of multiple sclerosis in Sweden," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 75-85, July.
    2. Karl Claxton & Simon Walker & Steven Palmer & Mark Sculpher, 2010. "Appropriate Perspectives for Health Care Decisions," Working Papers 054cherp, Centre for Health Economics, University of York.
    3. Jenny Berg & P. Lindgren & Sten Fredrikson & Gisela Kobelt, 2006. "Costs and quality of life of multiple sclerosis in Sweden," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(02), pages 75-85, July.
    4. Gisela Kobelt, 2006. "Costs and quality of life for patients with multiple sclerosis in Belgium," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 24-33, July.
    5. Gisela Kobelt & Jenny Berg & Peter Lindgren & W. Elias & P. Flachenecker & M. Freidel & N. König & V. Limmroth & E. Straube, 2006. "Costs and quality of life of multiple sclerosis in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 34-44, July.
    6. MerriKay Oleen-Burkey & Jane Castelli-Haley & Maureen Lage & Kenneth Johnson, 2012. "Burden of a Multiple Sclerosis Relapse," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 5(1), pages 57-69, March.
    7. Gisela Kobelt & Jenny Berg & Peter Lindgren & Carlotta Plesnilla & Ulf Baumhackl & Thomas Berger & Harald Kolleger & Karl Vass, 2006. "Costs and quality of life of multiple sclerosis in Austria," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 14-23, July.
    8. Joel Thompson & Amir Abdolahi & Katia Noyes, 2013. "Modelling the Cost Effectiveness of Disease-Modifying Treatments for Multiple Sclerosis," PharmacoEconomics, Springer, vol. 31(6), pages 455-469, June.
    9. Gisela Kobelt & Jenny Berg & P. Lindgren & J. Kerrigan & N. Russell & R. Nixon, 2006. "Costs and quality of life of multiple sclerosis in the United Kingdom," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 96-104, July.
    10. Gisela Kobelt, 2006. "Costs and quality of life for patients with multiple sclerosis in Belgium," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(02), pages 24-33, July.
    11. Gisela Kobelt & Jenny Berg & Peter Lindgren & M. Battaglia & C. Lucioni & A. Uccelli, 2006. "Costs and quality of life of multiple sclerosis in Italy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 45-54, July.
    12. Annie Hawton & James Shearer & Elizabeth Goodwin & Colin Green, 2013. "Squinting Through Layers of Fog: Assessing the Cost Effectiveness of Treatments for Multiple Sclerosis," Applied Health Economics and Health Policy, Springer, vol. 11(4), pages 331-341, August.
    13. Green, Gill & Todd, Jennifer & Pevalin, David, 2007. "Biographical disruption associated with multiple sclerosis: Using propensity scoring to assess the impact," Social Science & Medicine, Elsevier, vol. 65(3), pages 524-535, August.
    14. Gisela Kobelt & Jenny Berg & Peter Lindgren & W. Elias & P. Flachenecker & M. Freidel & N. König & V. Limmroth & E. Straube, 2006. "Costs and quality of life of multiple sclerosis in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(02), pages 34-44, July.
    15. Gisela Kobelt & Jenny Berg & P. Lindgren & J. Kerrigan & N. Russell & R. Nixon, 2006. "Costs and quality of life of multiple sclerosis in the United Kingdom," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(02), pages 96-104, July.
    16. Kobelt, Gisela & Jönsson, Linus & Fredriksson, Sten & Jönsson, Bengt, 2001. "Cost-utility analysis of Interferon Beta-1b in the treatment of different types of Multiple Sclerosis," SSE/EFI Working Paper Series in Economics and Finance 459, Stockholm School of Economics.
    17. Gisela Kobelt & J. Berg & P. Lindgren & G. Izquierdo & O. Sánchez-Soliño & J. Pérez-Miranda & M. Casado, 2006. "Costs and quality of life of multiple sclerosis in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 65-74, July.
    18. Craig I Coleman & Matthew F Sidovar & Matthew S Roberts & Christine Kohn, 2013. "Impact of Mobility Impairment on Indirect Costs and Health-Related Quality of Life in Multiple Sclerosis," PLOS ONE, Public Library of Science, vol. 8(1), pages 1-8, January.
    19. Gisela Kobelt & Jenny Berg & Peter Lindgren & Bengt Jönsson, 2006. "Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 5-13, July.

Articles

  1. Pickles, Kristen & Lancsar, Emily & Seymour, Janelle & Parkin, David & Donaldson, Cam & Carter, Stacy M., 2019. "Accounts from developers of generic health state utility instruments explain why they produce different QALYs: A qualitative study," Social Science & Medicine, Elsevier, vol. 240(C).

    Cited by:

    1. Nathan S. McClure & Mike Paulden & Arto Ohinmaa & Jeffrey A. Johnson, 2021. "Modifying the quality-adjusted life year calculation to account for meaningful change in health-related quality of life: insights from a pragmatic clinical trial," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(9), pages 1441-1451, December.
    2. Paul Mark Mitchell & Samantha Husbands & Sarah Byford & Philip Kinghorn & Cara Bailey & Tim J. Peters & Joanna Coast, 2021. "Challenges in developing capability measures for children and young people for use in the economic evaluation of health and care interventions," Health Economics, John Wiley & Sons, Ltd., vol. 30(9), pages 1990-2003, September.
    3. Joseph Carrello & Alison Hayes & Anagha Killedar & Amy Huben & Louise A. Baur & Stavros Petrou & Thomas Lung, 2021. "Utility Decrements Associated with Adult Overweight and Obesity in Australia: A Systematic Review and Meta-Analysis," PharmacoEconomics, Springer, vol. 39(5), pages 503-519, May.

  2. David Parkin & Nancy Devlin & Yan Feng, 2016. "What Determines the Shape of an EQ-5D Index Distribution?," Medical Decision Making, , vol. 36(8), pages 941-951, November.

    Cited by:

    1. Sang-Dol Kim, 2020. "Impacts of Sociodemographic Characteristics and Cardinal Health Problems on Health-Related Quality of Life among Korean Older Adults," Sustainability, MDPI, vol. 12(18), pages 1-9, September.
    2. Guizhi Weng & Yanming Hong & Nan Luo & Clara Mukuria & Jie Jiang & Zhihao Yang & Sha Li, 2023. "Comparing EQ-5D-3L and EQ-5D-5L in measuring the HRQoL burden of 4 health conditions in China," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(2), pages 197-207, March.

  3. Helen Dakin & Nancy Devlin & Yan Feng & Nigel Rice & Phill O'Neill & David Parkin, 2015. "The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions," Health Economics, John Wiley & Sons, Ltd., vol. 24(10), pages 1256-1271, October.
    See citations under working paper version above.
  4. David Nuttall & David Parkin & Nancy Devlin, 2015. "Inter‐Provider Comparison Of Patient‐Reported Outcomes: Developing An Adjustment To Account For Differences In Patient Case Mix," Health Economics, John Wiley & Sons, Ltd., vol. 24(1), pages 41-54, January.

    Cited by:

    1. Manuel Gomes & Nils Gutacker & Chris Bojke & Andrew Street, 2014. "Addressing missing data in patient-reported outcome measures (PROMs): implications for comparing provider performance," Working Papers 101cherp, Centre for Health Economics, University of York.
    2. Milena Vainieri & Guido Noto & Francesca Ferre & Laura C. Rosella, 2020. "A Performance Management System in Healthcare for All Seasons?," IJERPH, MDPI, vol. 17(15), pages 1-10, August.

  5. Nils Gutacker & Chris Bojke & Silvio Daidone & Nancy J. Devlin & David Parkin & Andrew Street, 2013. "Truly Inefficient Or Providing Better Quality Of Care? Analysing The Relationship Between Risk‐Adjusted Hospital Costs And Patients' Health Outcomes," Health Economics, John Wiley & Sons, Ltd., vol. 22(8), pages 931-947, August.
    See citations under working paper version above.
  6. Nancy J. Devlin & David Parkin & John Browne, 2010. "Patient‐reported outcome measures in the NHS: new methods for analysing and reporting EQ‐5D data," Health Economics, John Wiley & Sons, Ltd., vol. 19(8), pages 886-905, August.

    Cited by:

    1. Cristina Gutierrez-Delgado & Rosa-María Galindo-Suárez & Cesar Cruz-Santiago & Koonal Shah & Manny Papadimitropoulos & Yan Feng & Bernarda Zamora & Nancy Devlin, 2021. "EQ-5D-5L Health-State Values for the Mexican Population," Applied Health Economics and Health Policy, Springer, vol. 19(6), pages 905-914, November.
    2. Knott, R. & Lorgelly, P. & Black, N. & Hollingsworth, B., 2016. "Differential item functioning in the EQ-5D: An exploratory analysis using anchoring vignettes," Health, Econometrics and Data Group (HEDG) Working Papers 16/14, HEDG, c/o Department of Economics, University of York.
    3. Hareth Al-Janabi & Andrea Manca & Joanna Coast, 2017. "Predicting carer health effects for use in economic evaluation," PLOS ONE, Public Library of Science, vol. 12(9), pages 1-18, September.
    4. Shaofan Chen & Bo Burström & Vibeke Sparring & Dongfu Qian & Kristina Burström, 2019. "Differential Impact of an Education-Based Intervention for Patients with Type 2 Diabetes Mellitus in Rural China," IJERPH, MDPI, vol. 16(15), pages 1-12, July.
    5. David Nuttall & David Parkin & Nancy Devlin, 2015. "Inter‐Provider Comparison Of Patient‐Reported Outcomes: Developing An Adjustment To Account For Differences In Patient Case Mix," Health Economics, John Wiley & Sons, Ltd., vol. 24(1), pages 41-54, January.
    6. Ian M. McCarthy, 2015. "Putting the Patient in Patient Reported Outcomes: A Robust Methodology for Health Outcomes Assessment," Health Economics, John Wiley & Sons, Ltd., vol. 24(12), pages 1588-1603, December.
    7. Nils Gutacker & Andrew Street, 2015. "Multidimensional performance assessment using dominance criteria," Working Papers 115cherp, Centre for Health Economics, University of York.
    8. Nils Gutacker & Andrew Street, 2018. "Multidimensional performance assessment of public sector organisations using dominance criteria," Health Economics, John Wiley & Sons, Ltd., vol. 27(2), pages 13-27, February.
    9. Knott, Rachel J. & Lorgelly, Paula K. & Black, Nicole & Hollingsworth, Bruce, 2017. "Differential item functioning in quality of life measurement: An analysis using anchoring vignettes," Social Science & Medicine, Elsevier, vol. 190(C), pages 247-255.
    10. McCarthy, Ian M., 2016. "Eliminating composite bias in treatment effects estimates: Applications to quality of life assessment," Journal of Health Economics, Elsevier, vol. 50(C), pages 47-58.
    11. Marta Rodríguez-Hernández & Juan-José Criado-Álvarez & Ana-Isabel Corregidor-Sánchez & José L. Martín-Conty & Alicia Mohedano-Moriano & Begoña Polonio-López, 2021. "Effects of Virtual Reality-Based Therapy on Quality of Life of Patients with Subacute Stroke: A Three-Month Follow-Up Randomized Controlled Trial," IJERPH, MDPI, vol. 18(6), pages 1-11, March.

  7. David Parkin & Nigel Rice & Nancy Devlin, 2010. "Statistical Analysis of EQ-5D Profiles: Does the Use of Value Sets Bias Inference?," Medical Decision Making, , vol. 30(5), pages 556-565, September.
    See citations under working paper version above.
  8. Sofia Dimakou & David Parkin & Nancy Devlin & John Appleby, 2009. "Identifying the impact of government targets on waiting times in the NHS," Health Care Management Science, Springer, vol. 12(1), pages 1-10, March.

    Cited by:

    1. Laudicella, M. & Siciliani, L. & Cookson, R., 2010. "Waiting Times and Socioeconomic Status: Evidence from England," Health, Econometrics and Data Group (HEDG) Working Papers 10/05, HEDG, c/o Department of Economics, University of York.
    2. Johansson, Kjell Arne & Nygaard, Elizabeth & Herlofsen, Berit & Lindemark, Frode, 2017. "Implementation of the 2013 amended Patients’ Rights Act in Norway: Clinical priority guidelines and access to specialised health care," Health Policy, Elsevier, vol. 121(4), pages 346-353.
    3. van de Vijsel, Aart R. & Engelfriet, Peter M. & Westert, Gert P., 2011. "Rendering hospital budgets volume based and open ended to reduce waiting lists: Does it work?," Health Policy, Elsevier, vol. 100(1), pages 60-70, April.
    4. Rossella Verzulli & Rowena Jacobs & Maria Goddard, 2011. "Do hospitals respond to greater autonomy? Evidence from the English NHS," Working Papers 064cherp, Centre for Health Economics, University of York.
    5. McClean, Sally & Gillespie, Jennifer & Garg, Lalit & Barton, Maria & Scotney, Bryan & Kullerton, Ken, 2014. "Using phase-type models to cost stroke patient care across health, social and community services," European Journal of Operational Research, Elsevier, vol. 236(1), pages 190-199.
    6. Roll, Kathrin & Stargardt, Tom & Schreyögg, Jonas, 2011. "Effect of type of insurance and income on waiting time for outpatient care," hche Research Papers 2011/03, University of Hamburg, Hamburg Center for Health Economics (hche).
    7. Meliyanni Johar & Glenn Stewart Jones & Elizabeth Savage, 2013. "Emergency Admissions And Elective Surgery Waiting Times," Health Economics, John Wiley & Sons, Ltd., vol. 22(6), pages 749-756, June.
    8. Jan Erik Askildsen & Tor Helge Holmås & Oddvar Kaarboe, 2011. "Monitoring prioritisation in the public health‐care sector by use of medical guidelines. The case of Norway," Health Economics, John Wiley & Sons, Ltd., vol. 20(8), pages 958-970, August.
    9. Askildsen, Jan Erik & Holmås, Tor Helge & Kaarboe, Oddvar, 2010. "Prioritization and patients' rights: Analysing the effect of a reform in the Norwegian hospital sector," Social Science & Medicine, Elsevier, vol. 70(2), pages 199-208, January.
    10. World Bank, 2015. "Bulgaria Health Financing," World Bank Publications - Reports 22964, The World Bank Group.
    11. Meliyanni Johar & Glenn Jones & Michael Keane & Elizabeth Savage & Olena Stavrunova, 2011. "Discrimination in a Universal Health System: Explaining Socioeconomic Waiting Time Gaps," Working Paper Series 165, Finance Discipline Group, UTS Business School, University of Technology, Sydney.
    12. Elsa Marques & Sian Noble & Ashley W. Blom & William Hollingworth, 2014. "Disclosing Total Waiting Times For Joint Replacement: Evidence From The English Nhs Using Linked Hes Data," Health Economics, John Wiley & Sons, Ltd., vol. 23(7), pages 806-820, July.
    13. Stephanie Thomas, 2016. "A Standardized Method for the Evaluation of Adherence to Practice Guidelines," Department of Economics Working Papers 2016-14, McMaster University.
    14. Dixon, Huw & Siciliani, Luigi, 2009. "Waiting-time targets in the healthcare sector: How long are we waiting?," Journal of Health Economics, Elsevier, vol. 28(6), pages 1081-1098, December.
    15. Nils Gutacker & Richard Cookson & Luigi Siciliani, 2015. "Waiting time prioritisation: evidence from England," Working Papers 114cherp, Centre for Health Economics, University of York.
    16. Dixon, Huw David & Siciliani, Luigi, 2009. "Waiting-time targets in healthcare markets: How long are we waiting?," CEPR Discussion Papers 7261, C.E.P.R. Discussion Papers.
    17. Sofia Dimakou & Ourania Dimakou & Henrique Basso, 2015. "Waiting time distribution in public health care: empirics and theory," Health Economics Review, Springer, vol. 5(1), pages 1-27, December.
    18. Kedai Cheng & Derek S. Young, 2020. "Tolerance intervals for autoregressive models, with an application to hospital waiting lists," Applied Stochastic Models in Business and Industry, John Wiley & Sons, vol. 36(2), pages 268-282, March.
    19. Januleviciute, Jurgita & Askildsen, Jan Erik & Kaarboe, Oddvar & Holmås, Tor Helge & Sutton, Matt, 2013. "The impact of different prioritisation policies on waiting times: Case studies of Norway and Scotland," Social Science & Medicine, Elsevier, vol. 97(C), pages 1-6.
    20. Sofia Dimakou & Ourania Dimakou & Henrique S. Basso, 2015. "The Asymmetric Effects of Waiting Time Targets in Health Care," BCAM Working Papers 1502, Birkbeck Centre for Applied Macroeconomics.
    21. Silviya Nikolova; & Arthur Sinko; & Matt Sutton;, 2012. "Do maximum waiting times guarantees change clinical priorities? A Conditional Density Estimation approach," Health, Econometrics and Data Group (HEDG) Working Papers 12/07, HEDG, c/o Department of Economics, University of York.
    22. Januleviciute, Jurgita & Askildsen, Jan Erik & Holmås, Tor Helge & Kaarbøe, Oddvar & Sutton, Matt, 2010. "The Impact of Different Prioritisation Policies on Waiting Times: A Comparative Analysis of Norway and Scotland," Working Papers in Economics 07/10, University of Bergen, Department of Economics.
    23. Shimaa Elkomy & Graham Cookson, 2020. "Performance Management Strategy: Waiting Time in the English National Health Services," Public Organization Review, Springer, vol. 20(1), pages 95-112, March.
    24. Siciliani, L., 2016. "Waiting Time Policies in the Health Sector," Seminar Briefing 001724, Office of Health Economics.
    25. Nikolova, Silviya & Sinko, Arthur & Sutton, Matt, 2015. "Do maximum waiting times guarantees change clinical priorities for elective treatment? Evidence from Scotland," Journal of Health Economics, Elsevier, vol. 41(C), pages 72-88.
    26. Rossella Verzulli & Rowena Jacobs & Maria Goddard, 2018. "Autonomy and performance in the public sector: the experience of English NHS hospitals," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 607-626, May.

  9. Appleby, John & Devlin, Nancy & Parkin, David & Buxton, Martin & Chalkidou, Kalipso, 2009. "Searching for cost effectiveness thresholds in the NHS," Health Policy, Elsevier, vol. 91(3), pages 239-245, August.

    Cited by:

    1. Mara Airoldi & Alec Morton & Jenifer A. E. Smith & Gwyn Bevan, 2014. "STAR—People-Powered Prioritization," Medical Decision Making, , vol. 34(8), pages 965-975, November.
    2. E. Wetering & E. Stolk & N. Exel & W. Brouwer, 2013. "Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 107-115, February.
    3. Jonathan Karnon & Andrew Partington & Hossein Afzali, 2022. "Strategies for Avoiding Neglect of Opportunity Costs by Decision-Makers," Applied Health Economics and Health Policy, Springer, vol. 20(1), pages 9-11, January.
    4. Adrian Towse;Paul Barnsley;Sarah Karlsberg-Schaffer;Jon Sussex, 2013. "Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold," Occasional Paper 000106, Office of Health Economics.
    5. Karl Claxton & Simon Walker & Steven Palmer & Mark Sculpher, 2010. "Appropriate Perspectives for Health Care Decisions," Working Papers 054cherp, Centre for Health Economics, University of York.
    6. Stefano Capri & Rosella Levaggi, 2011. "Shifting the risk in pricing and reimbursement schemes? A model of risk-sharing agreements for innovative drugs," DEP - series of economic working papers 2/2011, University of Genoa, Research Doctorate in Public Economics.
    7. Vincent T Janmaat & Marco J Bruno & Suzanne Polinder & Sylvie Lorenzen & Florian Lordick & Maikel P Peppelenbosch & Manon C W Spaander, 2016. "Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma," PLOS ONE, Public Library of Science, vol. 11(4), pages 1-10, April.
    8. Aidan Hollis, 2016. "Sustainable Financing of Innovative Therapies: A Review of Approaches," PharmacoEconomics, Springer, vol. 34(10), pages 971-980, October.
    9. Levaggi, Rosella, 2014. "Pricing schemes for new drugs: A welfare analysis," Social Science & Medicine, Elsevier, vol. 102(C), pages 69-73.
    10. Perry-duxbury, Megan & Lomas, James & Asaria, Miqdad & Van Baal, Pieter, 2022. "The relevance of including future healthcare costs in cost-effectiveness threshold calculations for the UK NHS," LSE Research Online Documents on Economics 112503, London School of Economics and Political Science, LSE Library.
    11. Siverskog, Jonathan & Henriksson, Martin, 2022. "The health cost of reducing hospital bed capacity," Social Science & Medicine, Elsevier, vol. 313(C).
    12. Magnus Johannesson;Bengt Jonsson;Linus Jonsson;Gisela Kobelt;Niklas Zethraeus, 2009. "Why Should Economic Evaluations of Medical Innovations Have a Societal Perspective?," Briefing 000228, Office of Health Economics.
    13. Helen Dakin & Nancy Devlin & Yan Feng & Nigel Rice & Phill O'Neill & David Parkin, 2015. "The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions," Health Economics, John Wiley & Sons, Ltd., vol. 24(10), pages 1256-1271, October.
    14. Laura Levaggi & Rosella Levaggi, 2017. "Rationing in health care provision: a welfare approach," International Journal of Health Economics and Management, Springer, vol. 17(2), pages 235-249, June.
    15. James Lomas & Jessica Ochalek & Rita Faria, 2022. "Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment," Applied Health Economics and Health Policy, Springer, vol. 20(1), pages 13-18, January.
    16. Laura Catherine Edney & Hossein Haji Ali Afzali & Terence Chai Cheng & Jonathan Karnon, 2018. "Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System," PharmacoEconomics, Springer, vol. 36(2), pages 239-252, February.
    17. Chris Schilling & Duncan Mortimer & Kim Dalziel, 2017. "Using CART to Identify Thresholds and Hierarchies in the Determinants of Funding Decisions," Medical Decision Making, , vol. 37(2), pages 173-182, February.
    18. James F. O’Mahony & Mike Paulden & Chris McCabe, 2021. "NICE’s Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests," PharmacoEconomics, Springer, vol. 39(2), pages 139-146, February.
    19. Jessica Ochalek & Karl Claxton & Paul Revill & Mark Sculpher & Alexandra Rollinger, 2016. "Supporting the development of an essential health package: principles and initial assessment for Malawi," Working Papers 136cherp, Centre for Health Economics, University of York.
    20. Jonathan Siverskog & Martin Henriksson, 2020. "Mutually Exclusive Interventions in the Cost-Effectiveness Bookshelf," Medical Decision Making, , vol. 40(3), pages 399-403, April.
    21. Laura Levaggi & Rosella Levaggi, 2016. "Welfare analysis of rationing in health care provision," Working papers 39, Società Italiana di Economia Pubblica.
    22. John McKie & Bradley Shrimpton & Jeff Richardson & Rosalind Hurworth, 2011. "The monetary value of a life year: evidence from a qualitative study of treatment costs," Health Economics, John Wiley & Sons, Ltd., vol. 20(8), pages 945-957, August.
    23. Laura Levaggi & Rosella Levaggi, 2011. "Welfare properties of restrictions to health care based on cost effectiveness," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 101-110, January.
    24. Kristian Bolin & Lars Forsgren, 2012. "The Cost Effectiveness of Newer Epilepsy Treatments," PharmacoEconomics, Springer, vol. 30(10), pages 903-923, October.
    25. Martina Garau & Grace Hampson & Nancy Devlin & Nicola Amedeo Mazzanti & Antonio Profico, 2018. "Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)," PharmacoEconomics - Open, Springer, vol. 2(2), pages 153-163, June.
    26. Chris Sampson & Bernarda Zamora & Sam Watson & John Cairns & Kalipso Chalkidou & Patricia Cubi-Molla & Nancy Devlin & Borja García-Lorenzo & Dyfrig A. Hughes & Ashley A. Leech & Adrian Towse, 2022. "Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy," Applied Health Economics and Health Policy, Springer, vol. 20(5), pages 651-667, September.
    27. Stephen Martin & Nigel Rice & Peter C. Smith, 2012. "Comparing costs and outcomes across programmes of health care," Health Economics, John Wiley & Sons, Ltd., vol. 21(3), pages 316-337, March.
    28. Karlsberg Schaffer, Sarah & Sussex, Jon & Devlin, Nancy & Walker, Andrew, 2015. "Local health care expenditure plans and their opportunity costs," Health Policy, Elsevier, vol. 119(9), pages 1237-1244.

  10. David Parkin & Nancy Devlin, 2006. "Is there a case for using visual analogue scale valuations in cost‐utility analysis?," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 653-664, July.
    See citations under working paper version above.
  11. Nancy Devlin & David Parkin, 2004. "Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 437-452, May.

    Cited by:

    1. Lakdawalla, Darius N. & Sun, Eric C. & Jena, Anupam B. & Reyes, Carolina M. & Goldman, Dana P. & Philipson, Tomas J., 2010. "An economic evaluation of the war on cancer," Journal of Health Economics, Elsevier, vol. 29(3), pages 333-346, May.
    2. Georgia Kourlaba & Vassilis Fragoulakis & Nikos Maniadakis, 2012. "Economic Evaluation of Clopidogrel in Acute Coronary Syndrome Patients without ST-Segment Elevation in Greece," Applied Health Economics and Health Policy, Springer, vol. 10(4), pages 261-271, July.
    3. Andrew M. Jones (ed.), 2012. "The Elgar Companion to Health Economics, Second Edition," Books, Edward Elgar Publishing, number 14021.
    4. Naiyana Praditsitthikorn & Yot Teerawattananon & Sripen Tantivess & Supon Limwattananon & Arthorn Riewpaiboon & Saibua Chichareon & Nantakan Ieumwananonthachai & Viroj Tangcharoensathien, 2011. "Economic Evaluation of Policy Options for Prevention and Control of Cervical Cancer in Thailand," PharmacoEconomics, Springer, vol. 29(9), pages 781-806, September.
    5. Mikael Svensson & Fredrik Nilsson & Karl Arnberg, 2015. "Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness," PharmacoEconomics, Springer, vol. 33(11), pages 1229-1236, November.
    6. E. Wetering & E. Stolk & N. Exel & W. Brouwer, 2013. "Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 107-115, February.
    7. Phill O’Neill & Nancy Devlin, 2010. "An Analysis of NICE’s ‘Restricted’ (or ‘Optimized’) Decisions," PharmacoEconomics, Springer, vol. 28(11), pages 987-993, November.
    8. John Vernon & Robert Goldberg & Joseph Golec, 2009. "Economic Evaluation and Cost-Effectiveness Thresholds," PharmacoEconomics, Springer, vol. 27(10), pages 797-806, October.
    9. Maynou, Laia & Cairns, John, 2018. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," LSE Research Online Documents on Economics 90877, London School of Economics and Political Science, LSE Library.
    10. Pedram Sendi, 2008. "Bridging the gap between health and non-health investments: moving from cost-effectiveness analysis to a return on investment approach across sectors of economy," International Journal of Health Economics and Management, Springer, vol. 8(2), pages 113-121, June.
    11. Javad Moradpour & Aidan Hollis, 2021. "The economic theory of cost‐effectiveness thresholds in health: Domestic and international implications," Health Economics, John Wiley & Sons, Ltd., vol. 30(5), pages 1139-1151, May.
    12. Gre[ss], Stefan & Niebuhr, Dea & Rothgang, Heinz & Wasem, Jurgen, 2005. "Criteria and procedures for determining benefit packages in health care: A comparative perspective," Health Policy, Elsevier, vol. 73(1), pages 78-91, July.
    13. Anthony J Culyer, 2015. "Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use," Working Papers 121cherp, Centre for Health Economics, University of York.
    14. Cairns, John, 2006. "Providing guidance to the NHS: The Scottish Medicines Consortium and the National Institute for Clinical Excellence compared," Health Policy, Elsevier, vol. 76(2), pages 134-143, April.
    15. Jennifer Whitty & Paul Scuffham & Sharyn Rundle-Thielee, 2011. "Public and decision maker stated preferences for pharmaceutical subsidy decisions," Applied Health Economics and Health Policy, Springer, vol. 9(2), pages 73-79, March.
    16. Dakin, Helen Angela & Devlin, Nancy J. & Odeyemi, Isaac A.O., 2006. ""Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making," Health Policy, Elsevier, vol. 77(3), pages 352-367, August.
    17. Andrew Foy & Christopher Sciamanna & Mark Kozak & Edward J. Filippone, 2014. "The Medical Care Cost Ratchet," Cato Journal, Cato Journal, Cato Institute, vol. 34(1), pages 83-98, Winter.
    18. Richard Norman & Gisselle Gallego, 2008. "Equity weights for economic evaluation: An Australian Discrete Choice Experiment, CHERE Working Paper 2008/5," Working Papers 2008/5, CHERE, University of Technology, Sydney.
    19. Gregory S. Zaric, 2008. "Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression," Health Economics, John Wiley & Sons, Ltd., vol. 17(11), pages 1277-1294, November.
    20. Neal Hockley, 2014. "Cost–Benefit Analysis: A Decision-Support Tool or a Venue for Contesting Ecosystem Knowledge?," Environment and Planning C, , vol. 32(2), pages 283-300, April.
    21. Thornton Snider Julia & Romley John A. & Vogt William B. & Philipson Tomas J., 2012. "The Option Value of Innovation," Forum for Health Economics & Policy, De Gruyter, vol. 15(2), pages 1-19, April.
    22. Jessica Ochalek & James Lomas & Karl Claxton, 2015. "Cost per DALY averted thresholds for low- and middle-income countries: evidence from cross country data," Working Papers 122cherp, Centre for Health Economics, University of York.
    23. Gu, Yuanyuan & Lancsar, Emily & Ghijben, Peter & Butler, James RG & Donaldson, Cam, 2015. "Attributes and weights in health care priority setting: A systematic review of what counts and to what extent," Social Science & Medicine, Elsevier, vol. 146(C), pages 41-52.
    24. Kanavos, Panos & Visintin, Erica & Gentilini, Arianna, 2023. "Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries," Social Science & Medicine, Elsevier, vol. 331(C).
    25. Hugh Gravelle & Stephen Morris & Matt Sutton, 2006. "Are General Practitioners Good for Endogenous Supply and Health," Working Papers 020cherp, Centre for Health Economics, University of York.
    26. Kate A Halton & David Cook & David L Paterson & Nasia Safdar & Nicholas Graves, 2010. "Cost-Effectiveness of a Central Venous Catheter Care Bundle," PLOS ONE, Public Library of Science, vol. 5(9), pages 1-11, September.
    27. Joanne Lord & George Laking & Alastair Fischer, 2006. "Non‐linearity in the cost‐effectiveness frontier," Health Economics, John Wiley & Sons, Ltd., vol. 15(6), pages 565-577, June.
    28. P. Beutels & W. J. Edmunds & R. D. Smith, 2008. "Partially wrong? Partial equilibrium and the economic analysis of public health emergencies of international concern," Health Economics, John Wiley & Sons, Ltd., vol. 17(11), pages 1317-1322, November.
    29. Tappenden, P & Brazier, J & Ratcliffe, J, 2006. "Does the National Institute for Health and Clinical Excellence take account of factors such as uncertainty and equity as well as incremental cost-effectiveness in commissioning health care services? A," MPRA Paper 29772, University Library of Munich, Germany.
    30. Peter Ghijben & Yuanyuan Gu & Emily Lancsar & Silva Zavarsek, 2018. "Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review," PharmacoEconomics, Springer, vol. 36(3), pages 323-340, March.
    31. Pieter van Baal & David Meltzer & Werner Brouwer, 2016. "Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost‐Effectiveness Analysis," Health Economics, John Wiley & Sons, Ltd., vol. 25(2), pages 237-248, February.
    32. Frans Rutten & Werner Brouwer & Louis Niessen, 2005. "Practice guidelines based on clinical and economic evidence," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(2), pages 91-93, June.
    33. James F. O’Mahony & Diarmuid Coughlan, 2016. "The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland’s Health System?," PharmacoEconomics, Springer, vol. 34(1), pages 5-11, January.
    34. Williams, Iestyn & Bryan, Stirling, 2007. "Understanding the limited impact of economic evaluation in health care resource allocation: A conceptual framework," Health Policy, Elsevier, vol. 80(1), pages 135-143, January.
    35. David Canning, 2009. "Axiomatic Foundations of Cost Effectiveness Analysis," PGDA Working Papers 5109, Program on the Global Demography of Aging.
    36. Chris Skedgel & Dominika Wranik & Min Hu, 2018. "The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian On," PharmacoEconomics, Springer, vol. 36(4), pages 467-475, April.
    37. Maynou, Laia & Cairns, John, 2019. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," Health Policy, Elsevier, vol. 123(2), pages 130-139.
    38. Fischer, Katharina E. & Rogowski, Wolf H. & Leidl, Reiner & Stollenwerk, Björn, 2013. "Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis," Health Policy, Elsevier, vol. 112(3), pages 187-196.
    39. Andrews, Brendon P., 2023. "Economic Evaluation under Ambiguity and Structural Uncertainties," Working Papers 2023-9, University of Alberta, Department of Economics, revised 05 Apr 2024.
    40. Hughes, David & Doheny, Shane, 2011. "Deliberating Tarceva: A case study of how British NHS managers decide whether to purchase a high-cost drug in the shadow of NICE guidance," Social Science & Medicine, Elsevier, vol. 73(10), pages 1460-1468.
    41. Girard, Dorota Zdanowska, 2005. "The cost of epidemiological transition: A study of a decrease in pertussis vaccination coverage," Health Policy, Elsevier, vol. 74(3), pages 287-303, November.
    42. Mark Nuijten & Wolfgang Wittenberg & Maximilian Lebmeier, 2007. "Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children," PharmacoEconomics, Springer, vol. 25(1), pages 55-71, January.
    43. Diane Dawson & Hugh Gravelle & Mary O'Mahony & Andrew Street & Martin Weale & Adriana Castelli & Rowena Jacobs & Paul Kind & Pete Loveridge & Stephen Martin & Philip Stevens & Lucy Stokes, 2005. "Developing new approaches to measuring NHS outputs and productivity," Working Papers 006cherp, Centre for Health Economics, University of York, revised Dec 2005.
    44. Henry Glick, 2011. "Sample Size and Power for Cost-Effectiveness Analysis (Part 1)," PharmacoEconomics, Springer, vol. 29(3), pages 189-198, March.
    45. John Henderson & Katharina Janke & Carol Propper, 2007. "Are current levels of air pollution in England too high? The impact of pollution on population mortality," CASE Papers case128, Centre for Analysis of Social Exclusion, LSE.
    46. Helen Campbell & Sue Tait & Linda Sharples & Noreen Caine & Timothy Gray & Peter Schofield & Martin Buxton, 2005. "Trial-based cost-utility comparison of percutaneous myocardial laser revascularisation and continued medical therapy for treatment of refractory angina pectoris," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(4), pages 288-297, December.
    47. Svensson, Mikael & Hultkrantz, Lars, 2012. "The Willingness to Pay for a QALY - Results based on value of statistical life estimates in Sweden," Karlstad University Working Papers in Economics 2, Karlstad University, Department of Economics.
    48. Samuel Shillcutt & Damian Walker & Catherine Goodman & Anne Mills, 2009. "Cost Effectiveness in Low- and Middle-Income Countries," PharmacoEconomics, Springer, vol. 27(11), pages 903-917, November.
    49. Katharina Fischer & Reiner Leidl, 2014. "Analysing coverage decision-making: opening Pandora’s box?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(9), pages 899-906, December.
    50. Grupo de Economía de la Salud & Jairo Humberto Restrepo, 2012. "Economía de las enfermedades crónicas no transmisibles: Implicaciones para Colombia," Observatorio Seguridad Social 15579, Grupo de Economía de la Salud.
    51. Susanne Schmitz & Laura McCullagh & Roisin Adams & Michael Barry & Cathal Walsh, 2016. "Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland," PharmacoEconomics, Springer, vol. 34(9), pages 925-937, September.
    52. Helen Dakin & Nancy Devlin & Yan Feng & Nigel Rice & Phill O'Neill & David Parkin, 2015. "The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions," Health Economics, John Wiley & Sons, Ltd., vol. 24(10), pages 1256-1271, October.
    53. Joseph P. Cook & Joseph Golec, 2017. "How excluding some benefits from value assessment of new drugs impacts innovation," Health Economics, John Wiley & Sons, Ltd., vol. 26(12), pages 1813-1825, December.
    54. Anthony Harris & Jing Jing Li & Karen Yong, 2016. "What Can We Expect from Value-Based Funding of Medicines? A Retrospective Study," PharmacoEconomics, Springer, vol. 34(4), pages 393-402, April.
    55. Simon Eckermann, 2015. "Kinky Thresholds Revisited: Opportunity Costs Differ in the NE and SW Quadrants," Applied Health Economics and Health Policy, Springer, vol. 13(1), pages 7-13, February.
    56. Mauskopf, Josephine & Chirila, Costel & Birt, Julie & Boye, Kristina S. & Bowman, Lee, 2013. "Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: Have they impacted the National Health Service budget?," Health Policy, Elsevier, vol. 110(1), pages 49-59.
    57. E. Stolk & M. Poley, 2005. "Criteria for determining a basic health services package," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(1), pages 2-7, March.
    58. Takeru Shiroiwa & Yoon‐Kyoung Sung & Takashi Fukuda & Hui‐Chu Lang & Sang‐Cheol Bae & Kiichiro Tsutani, 2010. "International survey on willingness‐to‐pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?," Health Economics, John Wiley & Sons, Ltd., vol. 19(4), pages 422-437, April.
    59. Stein, K & Dyer, M & Crabb, T & Milne, R & Round, A & Ratcliffe, J & Brazier, J, 2006. "An Internet “Value of Health” panel: recruitment, participation and compliance," MPRA Paper 29770, University Library of Munich, Germany.
    60. Elisa F Long & Roshni Mandalia & Sundhiya Mandalia & Sabina S Alistar & Eduard J Beck & Margaret L Brandeau, 2014. "Expanded HIV Testing in Low-Prevalence, High-Income Countries: A Cost-Effectiveness Analysis for the United Kingdom," PLOS ONE, Public Library of Science, vol. 9(4), pages 1-12, April.
    61. J. Raftery, 2014. "NICE’s Cost-Effectiveness Range: Should it be Lowered?," PharmacoEconomics, Springer, vol. 32(7), pages 613-615, July.
    62. Michał Jakubczyk & Bogumił Kamiński, 2017. "Fuzzy approach to decision analysis with multiple criteria and uncertainty in health technology assessment," Annals of Operations Research, Springer, vol. 251(1), pages 301-324, April.
    63. Colette Mankowski & Sachin Patel & David Trueman & Anthony Bentley & Chris Poole, 2016. "Cost-Effectiveness of Capsaicin 8% Patch Compared with Pregabalin for the Treatment of Patients with Peripheral Neuropathic Pain in Scotland," PLOS ONE, Public Library of Science, vol. 11(3), pages 1-16, March.
    64. Stavros Petrou & Ngianga-Bakwin Kandala & Angela Robinson & Rachel Baker, 2013. "A Person Trade-Off Study to Estimate Age-Related Weights for Health Gains in Economic Evaluation," PharmacoEconomics, Springer, vol. 31(10), pages 893-907, October.
    65. Colin Green & Karen Gerard, 2009. "Exploring the social value of health‐care interventions: a stated preference discrete choice experiment," Health Economics, John Wiley & Sons, Ltd., vol. 18(8), pages 951-976, August.
    66. Hodgetts, Katherine & Elshaug, Adam G. & Hiller, Janet E., 2012. "What counts and how to count it: Physicians’ constructions of evidence in a disinvestment context," Social Science & Medicine, Elsevier, vol. 75(12), pages 2191-2199.
    67. Reckers-Droog, V.T. & van Exel, N.J.A. & Brouwer, W.B.F., 2018. "Looking back and moving forward: On the application of proportional shortfall in healthcare priority setting in the Netherlands," Health Policy, Elsevier, vol. 122(6), pages 621-629.
    68. Christine McDonough & Anna Tosteson, 2007. "Measuring Preferences for Cost-Utility Analysis," PharmacoEconomics, Springer, vol. 25(2), pages 93-106, February.
    69. Michael Drummond, 2012. "Economic Evaluation and Decision-makers," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 54, Edward Elgar Publishing.
    70. Qi Gui & Xinghuo Zhang & Liang Liu & Feng Zhao & Wenhao Cheng & Yakui Zhang, 2019. "Cost-utility analysis of total knee arthroplasty for osteoarthritis in a regional medical center in China," Health Economics Review, Springer, vol. 9(1), pages 1-8, December.
    71. Fischer, Katharina E. & Leidl, Reiner & Rogowski, Wolf H., 2011. "A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and prevention," Health Policy, Elsevier, vol. 101(3), pages 290-299, August.
    72. Chris Schilling & Duncan Mortimer & Kim Dalziel, 2017. "Using CART to Identify Thresholds and Hierarchies in the Determinants of Funding Decisions," Medical Decision Making, , vol. 37(2), pages 173-182, February.
    73. Mattias Ekman & Peter Lindgren & Carolin Miltenburger & Genevieve Meier & Julie Locklear & Mary Chatterton, 2012. "Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive Episode," PharmacoEconomics, Springer, vol. 30(6), pages 513-530, June.
    74. Marta Osca-Guadalajara & Javier Díaz-Carnicero & Silvia González-de-Julián & David Vivas-Consuelo, 2021. "Markov Models for Economic Evaluation in Osteoporosis Treatment," Mathematics, MDPI, vol. 9(18), pages 1-20, September.
    75. Leonie Segal & Kim Dalziel & Duncan Mortimer, 2010. "Fixing the game: are between‐silo differences in funding arrangements handicapping some interventions and giving others a head‐start?," Health Economics, John Wiley & Sons, Ltd., vol. 19(4), pages 449-465, April.
    76. Jennifer A Whitty & Ruth Walker & Xanthe Golenko & Julie Ratcliffe, 2014. "A Think Aloud Study Comparing the Validity and Acceptability of Discrete Choice and Best Worst Scaling Methods," PLOS ONE, Public Library of Science, vol. 9(4), pages 1-9, April.
    77. James O’Mahony & Diarmuid Coughlan, 2016. "The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland’s Health System?," PharmacoEconomics, Springer, vol. 34(1), pages 5-11, January.
    78. Eric Deconinck & Houda Miadi-Fargier & Claude Pen & Pauline Brice, 2010. "Cost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma," PharmacoEconomics, Springer, vol. 28(1), pages 35-46, January.
    79. Eun-Young Bae & Hui Jeong Kim & Hye-Jae Lee & Junho Jang & Seung Min Lee & Yunkyung Jung & Nari Yoon & Tae Kyung Kim & Kookhee Kim & Bong-Min Yang, 2018. "Role of economic evidence in coverage decision-making in South Korea," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-12, October.
    80. Vuorenkoski, Lauri & Toiviainen, Hanna & Hemminki, Elina, 2008. "Decision-making in priority setting for medicines--A review of empirical studies," Health Policy, Elsevier, vol. 86(1), pages 1-9, April.
    81. Henry Glick, 2011. "Sample Size and Power for Cost-Effectiveness Analysis (Part 2)," PharmacoEconomics, Springer, vol. 29(4), pages 287-296, April.
    82. John McKie & Bradley Shrimpton & Jeff Richardson & Rosalind Hurworth, 2011. "The monetary value of a life year: evidence from a qualitative study of treatment costs," Health Economics, John Wiley & Sons, Ltd., vol. 20(8), pages 945-957, August.
    83. Martin Buxton, 2005. "How much are health-care systems prepared to pay to produce a QALY?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(4), pages 285-287, December.
    84. Wei Yang & Heather Gage & Daniel Jackson & Monique Raats, 2018. "The effectiveness and cost-effectiveness of plant sterol or stanol-enriched functional foods as a primary prevention strategy for people with cardiovascular disease risk in England: a modeling study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(7), pages 909-922, September.
    85. Fischer, Katharina Elisabeth & Heisser, Thomas & Stargardt, Tom, 2016. "Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia," Health Policy, Elsevier, vol. 120(10), pages 1115-1122.
    86. Laura Levaggi & Rosella Levaggi, 2011. "Welfare properties of restrictions to health care based on cost effectiveness," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 101-110, January.
    87. Christian R. C. Kouakou & Thomas G. Poder, 2022. "Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(2), pages 277-299, March.
    88. Praveen Thokala & Jessica Ochalek & Ashley A. Leech & Thaison Tong, 2018. "Cost-Effectiveness Thresholds: the Past, the Present and the Future," PharmacoEconomics, Springer, vol. 36(5), pages 509-522, May.
    89. Julien Forder, 2009. "Long‐term care and hospital utilisation by older people: an analysis of substitution rates," Health Economics, John Wiley & Sons, Ltd., vol. 18(11), pages 1322-1338, November.
    90. Kisser, Agnes & Tüchler, Heinz & Erdös, Judit & Wild, Claudia, 2016. "Factors influencing coverage decisions on medical devices: A retrospective analysis of 78 medical device appraisals for the Austrian hospital benefit catalogue 2008–2015," Health Policy, Elsevier, vol. 120(8), pages 903-912.
    91. Aris Angelis & Ansgar Lange & Panos Kanavos, 2018. "Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(1), pages 123-152, January.
    92. Michael Drummond, 2012. "Twenty Years of Using Economic Evaluations for Reimbursement Decisions. What Have We Achieved?," Working Papers 075cherp, Centre for Health Economics, University of York.
    93. Daniel Grima & Lisa Bernard & Elizabeth Dunn & Philip McFarlane & David Mendelssohn, 2012. "Cost-Effectiveness Analysis of Therapies for Chronic Kidney Disease Patients on Dialysis," PharmacoEconomics, Springer, vol. 30(11), pages 981-989, November.
    94. Georgia Kourlaba & Vassilis Fragoulakis & Nikos Maniadakis, 2012. "Clopidogrel versus Aspirin in Patients with Atherothrombosis," Applied Health Economics and Health Policy, Springer, vol. 10(5), pages 331-342, September.
    95. Malinowski, Krzysztof Piotr & Kawalec, Paweł & Trąbka, Wojciech, 2016. "Impact of patient outcomes and cost aspects on reimbursement recommendations in Poland in 2012–2014," Health Policy, Elsevier, vol. 120(11), pages 1249-1255.
    96. Tania Stafinski & Devidas Menon & Deborah Marshall & Timothy Caulfield, 2011. "Societal Values in the Allocation of Healthcare Resources," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 4(4), pages 207-225, December.
    97. Sonja Sorensen & Siyang Peng & Brigitta Monz & Carole Bradley-Kennedy & Anuraag Kansal, 2013. "A Comparative Analysis of Models Used to Evaluate the Cost-Effectiveness of Dabigatran Versus Warfarin for the Prevention of Stroke in Atrial Fibrillation," PharmacoEconomics, Springer, vol. 31(7), pages 589-604, July.
    98. Kasper M. Johannesen & Karl Claxton & Mark J. Sculpher & Allan J. Wailoo, 2018. "How to design the cost‐effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework," Health Economics, John Wiley & Sons, Ltd., vol. 27(2), pages 41-54, February.
    99. Howley, P., 2016. "Valuing the benefits from health care interventions using life satisfaction data," Health, Econometrics and Data Group (HEDG) Working Papers 16/01, HEDG, c/o Department of Economics, University of York.
    100. Katharina E. Fischer & Björn Stollenwerk & Wolf H. Rogowski, 2013. "Link between Process and Appraisal in Coverage Decisions," Medical Decision Making, , vol. 33(8), pages 1009-1025, November.
    101. Dana Goldman & Darius Lakdawalla & Tomas J. Philipson & Wesley Yin, 2010. "Valuing health technologies at nice: recommendations for improved incorporation of treatment value in HTA," Health Economics, John Wiley & Sons, Ltd., vol. 19(10), pages 1109-1116, October.
    102. Katharina Janke & Carol Propper & John Henderson, 2009. "Do current levels of air pollution kill? The impact of air pollution on population mortality in England," Health Economics, John Wiley & Sons, Ltd., vol. 18(9), pages 1031-1055, September.
    103. Margreet Franken & Fredrik Nilsson & Frank Sandmann & Anthonius Boer & Marc Koopmanschap, 2013. "Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making," PharmacoEconomics, Springer, vol. 31(9), pages 781-797, September.
    104. Warren Linley & Dyfrig Hughes, 2013. "Decision-Makers’ Preferences for Approving New Medicines in Wales: A Discrete-Choice Experiment with Assessment of External Validity," PharmacoEconomics, Springer, vol. 31(4), pages 345-355, April.
    105. Chris Sampson & Bernarda Zamora & Sam Watson & John Cairns & Kalipso Chalkidou & Patricia Cubi-Molla & Nancy Devlin & Borja García-Lorenzo & Dyfrig A. Hughes & Ashley A. Leech & Adrian Towse, 2022. "Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy," Applied Health Economics and Health Policy, Springer, vol. 20(5), pages 651-667, September.
    106. Appleby, John & Devlin, Nancy & Parkin, David & Buxton, Martin & Chalkidou, Kalipso, 2009. "Searching for cost effectiveness thresholds in the NHS," Health Policy, Elsevier, vol. 91(3), pages 239-245, August.
    107. Warren Linley & Dyfrig Hughes, 2012. "Reimbursement Decisions of the All Wales Medicines Strategy Group," PharmacoEconomics, Springer, vol. 30(9), pages 779-794, September.
    108. Fischer, Katharina Elisabeth, 2012. "A systematic review of coverage decision-making on health technologies—Evidence from the real world," Health Policy, Elsevier, vol. 107(2), pages 218-230.

  12. Parkin, David & Rice, Nigel & Jacoby, Ann & Doughty, Julie, 2004. "Use of a visual analogue scale in a daily patient diary: modelling cross-sectional time-series data on health-related quality of life," Social Science & Medicine, Elsevier, vol. 59(2), pages 351-360, July.

    Cited by:

    1. David Parkin & Nancy Devlin, 2006. "Is there a case for using visual analogue scale valuations in cost‐utility analysis?," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 653-664, July.
    2. Amir Shmueli & David Messika & Havi Murad & Laurence Freedman, 2008. "Does greater exposure to own-health data make a difference on the visual analog scale?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 9(1), pages 63-67, February.
    3. Costa-Font, Montserrat & Costa-Font, Joan, 2009. "Heterogeneous 'adaptation' and 'income effects' across self-reported health distribution?," Journal of Behavioral and Experimental Economics (formerly The Journal of Socio-Economics), Elsevier, vol. 38(4), pages 574-580, August.
    4. Uwe Zettl & Thomas Henze & Ute Essner & Peter Flachenecker, 2014. "Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I)," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(9), pages 953-966, December.

  13. Wolfgang Greiner & Tom Weijnen & Martin Nieuwenhuizen & Siem Oppe & Xavier Badia & Jan Busschbach & Martin Buxton & Paul Dolan & Paul Kind & Paul Krabbe & Arto Ohinmaa & David Parkin & Montserat Roset, 2003. "A single European currency for EQ-5D health states," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 4(3), pages 222-231, September.

    Cited by:

    1. Mark Oppe & Daniela Ortín-Sulbarán & Carlos Vila Silván & Anabel Estévez-Carrillo & Juan M. Ramos-Goñi, 2021. "Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(5), pages 711-721, July.
    2. Mathieu F. Janssen & A. Simon Pickard & James W. Shaw, 2021. "General population normative data for the EQ-5D-3L in the five largest European economies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(9), pages 1467-1475, December.
    3. Raymond Oppong & Billingsley Kaambwa & Jacqueline Nuttall & Kerenza Hood & Richard Smith & Joanna Coast, 2013. "The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(2), pages 197-209, April.
    4. Petra Menn & Reiner Leidl & Rolf Holle, 2012. "A Lifetime Markov Model for the Economic Evaluation of Chronic Obstructive Pulmonary Disease," PharmacoEconomics, Springer, vol. 30(9), pages 825-840, September.
    5. Cecilia Quercioli & Gabriele Messina & Emanuela Barbini & Giovanni Carriero & Mara Fanì & Nicola Nante, 2009. "Importance of sociodemographic and morbidity aspects in measuring health-related quality of life: performances of three tools," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 10(4), pages 389-397, October.
    6. Zsombor Zrubka & Dominik Golicki & Valentina Prevolnik-Rupel & Petra Baji & Fanni Rencz & Valentin Brodszky & László Gulácsi & Márta Péntek, 2019. "Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 141-154, June.
    7. Gapp, Oliver & Schweikert, Bernd & Meisinger, Christa & Holle, Rolf, 2008. "Disease management programmes for patients with coronary heart disease--An empirical study of German programmes," Health Policy, Elsevier, vol. 88(2-3), pages 176-185, December.
    8. Zsombor Zrubka & Zsuzsanna Beretzky & Zoltán Hermann & Valentin Brodszky & László Gulácsi & Fanni Rencz & Petra Baji & Dominik Golicki & Valentina Prevolnik-Rupel & Márta Péntek, 2019. "A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 119-132, June.
    9. Daniela Eidt-Koch & Wolfgang Greiner, 2011. "Quality of life results of balloon kyphoplasty versus non surgical management for osteoporotic vertebral fractures in Germany," Health Economics Review, Springer, vol. 1(1), pages 1-7, December.
    10. Irina Cleemput, 2010. "A social preference valuations set for EQ-5D health states in Flanders, Belgium," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(2), pages 205-213, April.
    11. Edward J. D. Webb & John O’Dwyer & David Meads & Paul Kind & Penny Wright, 2020. "Transforming discrete choice experiment latent scale values for EQ-5D-3L using the visual analogue scale," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(5), pages 787-800, July.

  14. Angela Robinson & David Parkin, 2002. "Recognising diversity in public preferences: the use of preference sub‐groups in cost‐effectiveness analysis. A response to Sculpher and Gafni," Health Economics, John Wiley & Sons, Ltd., vol. 11(7), pages 649-651, October.

    Cited by:

    1. Janneke Grutters & Mark Sculpher & Andrew Briggs & Johan Severens & Math Candel & James Stahl & Dirk Ruysscher & Albert Boer & Bram Ramaekers & Manuela Joore, 2013. "Acknowledging Patient Heterogeneity in Economic Evaluation," PharmacoEconomics, Springer, vol. 31(2), pages 111-123, February.
    2. Mark Sculpher & Amiram Gafni, 2002. "Recognising diversity in public preferences: the use of preference sub‐groups in cost‐effectiveness analysis. Authors' reply," Health Economics, John Wiley & Sons, Ltd., vol. 11(7), pages 653-654, October.
    3. Juan M. Ramos-Goñi & Mark Oppe & Elly Stolk & Koonal Shah & Simone Kreimeier & Oliver Rivero-Arias & Nancy Devlin, 2020. "International Valuation Protocol for the EQ-5D-Y-3L," PharmacoEconomics, Springer, vol. 38(7), pages 653-663, July.
    4. Jennifer Whitty & Emily Lancsar & Kylie Rixon & Xanthe Golenko & Julie Ratcliffe, 2014. "A Systematic Review of Stated Preference Studies Reporting Public Preferences for Healthcare Priority Setting," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 7(4), pages 365-386, December.
    5. Nancy J. Devlin & Koonal K. Shah & Yan Feng & Brendan Mulhern & Ben van Hout, 2018. "Valuing health‐related quality of life: An EQ‐5D‐5L value set for England," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 7-22, January.

  15. David Parkin & Nigel Rice & Matthew Sutton, 1999. "Non‐ and semi‐parametric estimation of age and time heterogeneity in repeated cross‐sections: an application to self‐reported morbidity and general practitioner utilization1," Health Economics, John Wiley & Sons, Ltd., vol. 8(5), pages 429-440, August.

    Cited by:

    1. Matthew Polisson, 2011. "Do waiting times matter in primary care? GP visits and list sizes in England," Economics Series Working Papers 541, University of Oxford, Department of Economics.
    2. Mason, Thomas & Sutton, Matt & Whittaker, William & Birch, Stephen, 2015. "Exploring the limitations of age-based models for health care planning," Social Science & Medicine, Elsevier, vol. 132(C), pages 11-19.
    3. Kosei Fukuda, 2007. "An empirical analysis of US and Japanese health insurance using age–period–cohort decomposition," Health Economics, John Wiley & Sons, Ltd., vol. 16(5), pages 475-489, May.

  16. David Parkin & Bruce Hollingsworth, 1997. "Measuring production efficiency of acute hospitals in Scotland, 1991-94: validity issues in data envelopment analysis," Applied Economics, Taylor & Francis Journals, vol. 29(11), pages 1425-1433.

    Cited by:

    1. Carlos Pestana Barros & António Gomes Menezes & José António Cabral Vieira, 2011. "Measurement of Hospital Efficiency, Using a Latent Class Stochastic Frontier Model," Post-Print hal-00732115, HAL.
    2. Duen-Yian Yeh & Ching-Hsue Cheng, 2016. "Performance Management of Taiwan’s National Hospitals," International Journal of Information Technology & Decision Making (IJITDM), World Scientific Publishing Co. Pte. Ltd., vol. 15(01), pages 187-213, January.
    3. Jacques Ngoie Kibambe & Steven F. Koch, 2005. "DEA Applied to a Gauteng Sample of South African Public Hospitals," Working Papers 200512, University of Pretoria, Department of Economics.
    4. Kao, Ling-Jing & Lu, Chi-Jie & Chiu, Chih-Chou, 2011. "Efficiency measurement using independent component analysis and data envelopment analysis," European Journal of Operational Research, Elsevier, vol. 210(2), pages 310-317, April.
    5. Nan Jiang & Antony Andrews, 2020. "Efficiency of New Zealand’s District Health Boards at Providing Hospital Services: A stochastic frontier analysis," Journal of Productivity Analysis, Springer, vol. 53(1), pages 53-68, February.
    6. N. Maniadakis & N. Kotsopoulos & P. Prezerakos & J. Yfantopoulos, 2009. "Health Care Services Performance Measurement: Theory, Methods and Empirical Evidence," European Research Studies Journal, European Research Studies Journal, vol. 0(3), pages 151-170.
    7. Johnston, Katharine & Gerard, Karen, 2001. "Assessing efficiency in the UK breast screening programme: does size of screening unit make a difference?," Health Policy, Elsevier, vol. 56(1), pages 21-32, April.
    8. Puenpatom, R. Amy & Rosenman, Robert, 2006. "Efficiency of Thai Provincial Public Hospitals after the Introduction of National Health Insurance Program," Working Papers 12960, Washington State University, School of Economic Sciences.
    9. Pompei, Fabrizio, 2013. "Efficiency And Productivity Growth Across The Italian Regions: The Regional Divide Revisited," MPRA Paper 52052, University Library of Munich, Germany.
    10. Sagarra, Marti & Mar-Molinero, Cecilio & Agasisti, Tommaso, 2017. "Exploring the efficiency of Mexican universities: Integrating Data Envelopment Analysis and Multidimensional Scaling," Omega, Elsevier, vol. 67(C), pages 123-133.
    11. Gannon, Brenda, 2004. "Technical Efficiency of Hospitals in Ireland," Papers HRBWP18, Economic and Social Research Institute (ESRI).
    12. Gannon, Brenda, 2005. "Testing for Variation in Technical Efficiency of Hospitals in Ireland," Papers HRBWP20, Economic and Social Research Institute (ESRI).
    13. Sepehrdoust Hamid, 2010. "Efficiency Measurement of Housing Sector in Iran," Asian Journal of Law and Economics, De Gruyter, vol. 1(2), pages 1-21, December.
    14. Yanfang Zhang & Mushang Lee, 2019. "A Hybrid Model for Addressing the Relationship between Financial Performance and Sustainable Development," Sustainability, MDPI, vol. 11(10), pages 1-15, May.
    15. Sadaf Hafeez & Noreen Izza Arshad & Lukman Bin A B Rahim & Muhammad Farooq Shabbir & Jawad Iqbal, 2020. "Innovation in Chinese internet companies: A meta-frontier analysis," PLOS ONE, Public Library of Science, vol. 15(5), pages 1-15, May.
    16. N. Maniadakis & N. Kotsopoulos & P. Prezerakos & J. Yfantopoulos, 2008. "Measuring Intra-Hospital Clinic Efficiency and Productivity: Application to a Greek University General Hospital," European Research Studies Journal, European Research Studies Journal, vol. 0(1-2), pages 95-110.
    17. Anastasios Trakakis & Miltiadis Nektarios & Styliani Tziaferi & Panagiotis Prezerakos, 2022. "Evaluation of the Efficiency in Public Health Centers in Greece Regarding the Human Resources Occupied: A Bootstrap Data Envelopment Analysis Application," IJERPH, MDPI, vol. 19(3), pages 1-13, January.
    18. Deng, Zhongqi & Jiang, Nan & Pang, Ruizhi, 2021. "Factor-analysis-based directional distance function: The case of New Zealand hospitals," Omega, Elsevier, vol. 98(C).
    19. Trakakis Anastasios & Nektarios Miltiadis & Tziaferi Styliani & Prezerakos Panagiotis, 2021. "Measuring Technical Efficiency of Health Centers in Greece: A Data Envelopment Analysis Application for the Primary Health System of Greece," European Research Studies Journal, European Research Studies Journal, vol. 0(Special 1), pages 1333-1353.
    20. Isabelle Piot-Lepetit, 1998. "Agriculture et environnement : une évaluation de la performance technique et environnementale d'exploitations bovines," Post-Print hal-02290696, HAL.
    21. Alexandre Marinho & Simone de Souza Cardoso & Vivian Vicente de Almeida, 2009. "Brasil e OCDE: Avaliação da Eficiência em Sistemas de Saúde," Discussion Papers 1370, Instituto de Pesquisa Econômica Aplicada - IPEA.
    22. Jonathan Cowie & Darinka Asenova, 1999. "Organisation form, scale effects and efficiency in the British bus industry," Transportation, Springer, vol. 26(3), pages 231-248, August.
    23. M I Gonzalez-Bravo, 2007. "Prior-Ratio-Analysis procedure to improve data envelopment analysis for performance measurement," Journal of the Operational Research Society, Palgrave Macmillan;The OR Society, vol. 58(9), pages 1214-1222, September.
    24. Bruce Hollingsworth & Anthony Harris & Elena Gospodarevskaya, 2002. "The efficiency of immunization of infants by local government," Applied Economics, Taylor & Francis Journals, vol. 34(18), pages 2341-2345.
    25. O'Neill, Liam & Rauner, Marion & Heidenberger, Kurt & Kraus, Markus, 2008. "A cross-national comparison and taxonomy of DEA-based hospital efficiency studies," Socio-Economic Planning Sciences, Elsevier, vol. 42(3), pages 158-189, September.
    26. Isabelle Piot-Lepetit & . Esr. Département d'Economie Et Sociologie Ruralesdijon, 1997. "Agriculture and environment : evaluation of environmental efficiency measurement of French bovine sector [Agriculture et environnement : une évaluation de la performance environnementale d'exploita," Post-Print hal-02841851, HAL.
    27. Kontodimopoulos, Nick & Niakas, Dimitris, 2005. "Efficiency measurement of hemodialysis units in Greece with data envelopment analysis," Health Policy, Elsevier, vol. 71(2), pages 195-204, February.
    28. Robert Stefko & Beata Gavurova & Kristina Kocisova, 2018. "Healthcare efficiency assessment using DEA analysis in the Slovak Republic," Health Economics Review, Springer, vol. 8(1), pages 1-12, December.
    29. Ahmed Mohamed Habib & Nahia Mourad, 2022. "Analyzing the Efficiency of Working Capital Management: a New Approach Based on DEA-Malmquist Technology," SN Operations Research Forum, Springer, vol. 3(3), pages 1-20, September.
    30. Varabyova, Yauheniya & Müller, Julia-Maria, 2016. "The efficiency of health care production in OECD countries: A systematic review and meta-analysis of cross-country comparisons," Health Policy, Elsevier, vol. 120(3), pages 252-263.
    31. Hamid Sepehrdoust & Adel Berjisian, 2011. "Economic Performance of Housing Sector in Iran," Iranian Economic Review (IER), Faculty of Economics,University of Tehran.Tehran,Iran, vol. 16(1), pages 13-27, winter.
    32. Kim-Huong Nguyen & Tim Coelli, 2009. "Quantifying the effects of modelling choices on hospital efficiency measures: A meta-regression analysis," CEPA Working Papers Series WP072009, School of Economics, University of Queensland, Australia.
    33. Bao Hoang Nguyen & Robin C. Sickles & Valentin Zelenyuk, 2021. "What do we know from the vast literature on efficiency and productivity in healthcare? A Systematic Review and Bibliometric Analysis," CEPA Working Papers Series WP092021, School of Economics, University of Queensland, Australia.
    34. Varabyova, Yauheniya & Schreyögg, Jonas, 2013. "International comparisons of the technical efficiency of the hospital sector: Panel data analysis of OECD countries using parametric and non-parametric approaches," Health Policy, Elsevier, vol. 112(1), pages 70-79.
    35. M M Segovia-Gonzalez & I Contreras & C Mar-Molinero, 2009. "A DEA analysis of risk, cost, and revenues in insurance," Journal of the Operational Research Society, Palgrave Macmillan;The OR Society, vol. 60(11), pages 1483-1494, November.
    36. Donal. G. McKillop & J. Colin Glass & Christine A. Kerr & Gillian McCallion, 1999. "Efficiency in Northern Ireland Hospitals - A Non-parametric Analysis," The Economic and Social Review, Economic and Social Studies, vol. 30(2), pages 175-196.

  17. Miller, Paul & Parkin, David & Craig, Neil & Lewis, David & Gerard, Karen, 1997. "Less fog on the Tyne? Programme budgeting in Newcastle and North Tyneside," Health Policy, Elsevier, vol. 40(3), pages 217-229, June.

    Cited by:

    1. Mitton, Craig & Donaldson, Cam, 2002. "Setting priorities in Canadian regional health authorities: a survey of key decision makers," Health Policy, Elsevier, vol. 60(1), pages 39-58, April.
    2. Stuart J. Peacock & Craig Mitton, 2012. "Priority Setting Methods in Health Services," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 53, Edward Elgar Publishing.
    3. Mitton, Craig R. & Donaldson, Cam, 2003. "Setting priorities and allocating resources in health regions: lessons from a project evaluating program budgeting and marginal analysis (PBMA)," Health Policy, Elsevier, vol. 64(3), pages 335-348, June.

  18. Anthony Scott & David Parkin, 1995. "Investigating hospital efficiency in the new NHS: The role of the translog cost function," Health Economics, John Wiley & Sons, Ltd., vol. 4(6), pages 467-478, November.

    Cited by:

    1. Monica Giancotti & Annamaria Guglielmo & Marianna Mauro, 2017. "Efficiency and optimal size of hospitals: Results of a systematic search," PLOS ONE, Public Library of Science, vol. 12(3), pages 1-40, March.
    2. Pankaj Bahuguna & Lorna Guinness & Sameer Sharma & Akashdeep Singh Chauhan & Laura Downey & Shankar Prinja, 2020. "Estimating the Unit Costs of Healthcare Service Delivery in India: Addressing Information Gaps for Price Setting and Health Technology Assessment," Applied Health Economics and Health Policy, Springer, vol. 18(5), pages 699-711, October.
    3. Vassilis H. Aletras, 1999. "A comparison of hospital scale effects in short‐run and long‐run cost functions," Health Economics, John Wiley & Sons, Ltd., vol. 8(6), pages 521-530, September.
    4. Wang, Jian & Zhao, Zhong & Mahmood, Amir, 2006. "Relative Efficiency, Scale Effect, and Scope Effect of Public Hospitals: Evidence from Australia," IZA Discussion Papers 2520, Institute of Labor Economics (IZA).
    5. Alexander S. Preker & Xingzhu Liu & Edit V. Velenyi & Enis Baris, 2007. "Public Ends, Private Means : Strategic Purchasing of Health Services," World Bank Publications - Books, The World Bank Group, number 6683, December.
    6. Albert A. Okunade & Chutima Suraratdecha, 1998. "Cost efficiency, factor interchange, and technical progress in US specialized hospital pharmacies," Health Economics, John Wiley & Sons, Ltd., vol. 7(4), pages 363-371, June.
    7. Giuffrida, Antonio & Gravelle, Hugh & Sutton, Matthew, 2000. "Efficiency and administrative costs in primary care," Journal of Health Economics, Elsevier, vol. 19(6), pages 983-1006, November.
    8. Oliveira, Monica D. & Bevan, Gwyn, 2008. "Modelling hospital costs to produce evidence for policies that promote equity and efficiency," European Journal of Operational Research, Elsevier, vol. 185(3), pages 933-947, March.
    9. Liu, Xingzhu & Hotchkiss, David R. & Bose, Sujata, 2007. "The impact of contracting-out on health system performance: A conceptual framework," Health Policy, Elsevier, vol. 82(2), pages 200-211, July.
    10. Suraratdecha, Chutima & Okunade, Albert A., 2006. "Measuring operational efficiency in a health care system: A case study from Thailand," Health Policy, Elsevier, vol. 77(1), pages 2-23, June.
    11. Productivity Commission, 2009. "Public and Private Hospitals," Research Reports, Productivity Commission, Government of Australia, number 37.
    12. Alessandra Ferrari, 2006. "NHS Reforms and efficiency of hospital services: a stochastic distance function apporach," Economic Analysis Research Group Working Papers earg-wp2006-06, Henley Business School, University of Reading.

  19. Craig, Neil & Parkin, David & Gerard, Karen, 1995. "Clearing the fog on the Tyne: programme budgeting in Newcastle and North Tyneside Health Authority," Health Policy, Elsevier, vol. 33(2), pages 107-125, August.

    Cited by:

    1. Stephen Jan, 2000. "Institutional considerations in priority setting: transactions cost perspective on PBMA," Health Economics, John Wiley & Sons, Ltd., vol. 9(7), pages 631-641, October.
    2. Holmes, Richard D. & Bate, Angela & Steele, Jimmy G. & Donaldson, Cam, 2009. "Commissioning NHS dentistry in England: Issues for decision-makers managing the new contract with finite resources," Health Policy, Elsevier, vol. 91(1), pages 79-88, June.
    3. Donaldson, Cam, 1995. "Economics, public health and health care purchasing: reinventing the wheel?," Health Policy, Elsevier, vol. 33(2), pages 79-90, August.
    4. Haas, Marion & Viney, Rosalie & Kristensen, Elizabeth & Pain, Charles & Foulds, Kim, 2001. "Using programme budgeting and marginal analysis to assist population based strategic planning for coronary heart disease," Health Policy, Elsevier, vol. 55(3), pages 173-186, March.
    5. Twaddle, Sara & Walker, Andrew, 1995. "Programme budgeting and marginal analysis: application within programmes to assist purchasing in Greater Glasgow Health Board," Health Policy, Elsevier, vol. 33(2), pages 91-105, August.
    6. Mitton, Craig R. & Donaldson, Cam, 2003. "Setting priorities and allocating resources in health regions: lessons from a project evaluating program budgeting and marginal analysis (PBMA)," Health Policy, Elsevier, vol. 64(3), pages 335-348, June.
    7. Miller, Paul & Parkin, David & Craig, Neil & Lewis, David & Gerard, Karen, 1997. "Less fog on the Tyne? Programme budgeting in Newcastle and North Tyneside," Health Policy, Elsevier, vol. 40(3), pages 217-229, June.
    8. Cornelissen, Evelyn & Mitton, Craig & Davidson, Alan & Reid, R. Colin & Hole, Rachelle & Visockas, Anne-Marie & Smith, Neale, 2014. "Changing priority setting practice: The role of implementation in practice change," Health Policy, Elsevier, vol. 117(2), pages 266-274.

  20. Bryan, Stirling & Parkin, David & Donaldson, Cam, 1991. "Chiropody and the QALY: a case study in assigning categories of disability and distress to patients," Health Policy, Elsevier, vol. 18(2), pages 169-185, July.

    Cited by:

    1. Donaldson, Cam, 1995. "Economics, public health and health care purchasing: reinventing the wheel?," Health Policy, Elsevier, vol. 33(2), pages 79-90, August.
    2. Wiseman, Virginia & Mooney, Gavin, 1998. "SOUNDING BOARD: Burden of illness estimates for priority setting: a debate revisited," Health Policy, Elsevier, vol. 43(3), pages 243-251, March.
    3. Karen Gerard & Gavin Mooney, 1993. "Qaly league tables: Handle with care," Health Economics, John Wiley & Sons, Ltd., vol. 2(1), pages 59-64, April.
    4. Stavros Petrou & Christine Hockley, 2005. "An investigation into the empirical validity of the EQ‐5D and SF‐6D based on hypothetical preferences in a general population," Health Economics, John Wiley & Sons, Ltd., vol. 14(11), pages 1169-1189, November.
    5. Lisa Prosser & James Hammitt & Ron Keren, 2007. "Measuring Health Preferences for Use in Cost-Utility and Cost-Benefit Analyses of Interventions in Children," PharmacoEconomics, Springer, vol. 25(9), pages 713-726, September.

  21. Parkin, David, 1989. "Comparing Health Service Efficiency Across Countries," Oxford Review of Economic Policy, Oxford University Press and Oxford Review of Economic Policy Limited, vol. 5(1), pages 75-88, Spring.

    Cited by:

    1. Suhrcke, Marc, 2000. "Are reforms from a centrally planned to a market system bad for health?," HWWA Discussion Papers 105, Hamburg Institute of International Economics (HWWA).

  22. Parkin, David & McGuire, Alistair & Yule, Brian, 1987. "Aggregate health care expenditures and national income : Is health care a luxury good?," Journal of Health Economics, Elsevier, vol. 6(2), pages 109-127, June.

    Cited by:

    1. Rivera, Berta & Currais, Luis, 2004. "Public Health Capital and Productivity in the Spanish Regions: A Dynamic Panel Data Model," World Development, Elsevier, vol. 32(5), pages 871-885, May.
    2. L. Di Matteo & Tom Barbiero, 2019. "Spend Less, Get More? Explaining Health Spending and Outcome Differences Between Canada and Italy," Working Papers 077, Ryerson University, Department of Economics.
    3. Andree Ehlert & Dirk Oberschachtsiek & Stefan Prawda, 2013. "Cost Containment and Managed Care: Evidence from German Macro Data," Working Paper Series in Economics 284, University of Lüneburg, Institute of Economics.
    4. Badi H. Baltagi & Raffaele Lagravinese & Francesco Moscone & Elisa Tosetti, 2016. "The Health Care Expenditure and Income: A Global Perspective," Center for Policy Research Working Papers 197, Center for Policy Research, Maxwell School, Syracuse University.
    5. Tom Jefferson & Miranda Mugford & Alastair Gray & Vittorio Demicheli, 1996. "An exercise on the feasibility of carrying out secondary economic analyses," Health Economics, John Wiley & Sons, Ltd., vol. 5(2), pages 155-165, March.
    6. Bergh, Andreas, 2016. "The Future of Welfare Services: How Worried Should We Be about Wagner, Baumol and Ageing?," Working Paper Series 1109, Research Institute of Industrial Economics.
    7. Yihua Yu & Li Zhang & Fanghua Li & Xinye Zheng, 2013. "Strategic interaction and the determinants of public health expenditures in China: a spatial panel perspective," The Annals of Regional Science, Springer;Western Regional Science Association, vol. 50(1), pages 203-221, February.
    8. Jewell, Todd & Lee, Junsoo & Tieslau, Margie & Strazicich, Mark C., 2003. "Stationarity of health expenditures and GDP: evidence from panel unit root tests with heterogeneous structural breaks," Journal of Health Economics, Elsevier, vol. 22(2), pages 313-323, March.
    9. Mocan, H. Naci & Tekin, Erdal & Zax, Jeffrey S., 2004. "The Demand for Medical Care in Urban China," World Development, Elsevier, vol. 32(2), pages 289-304, February.
    10. Guillem López-Casasnovas & Berta Rivera, 2002. "Las políticas de equidad en salud y las relaciones entre renta y salud," Hacienda Pública Española / Review of Public Economics, IEF, vol. 161(2), pages 99-126, June.
    11. Kong, Moon-Kee & Lee, Hoe-Kyung, 1999. "Demand for medical care, consumption and cointegration," Economics Letters, Elsevier, vol. 62(3), pages 325-330, March.
    12. Manuel A.Gómez & Luis C.Currais, 2001. "Income variation, endogenous population growth and health subsidy," Estudios de Economia, University of Chile, Department of Economics, vol. 28(2 Year 20), pages 165-181, December.
    13. Oliver Fritz & Peter Mayerhofer & Reinhard Haller & Gerhard Streicher & Florian Bachner & Herwig Ostermann, 2013. "Die regionalwirtschaftlichen Effekte der österreichischen Krankenanstalten," WIFO Studies, WIFO, number 46672, April.
    14. Rita De Siano & Marcella D'Uva, 2013. "Does decentralization affect regional public spending in Italy?," Discussion Papers 1_2013, CRISEI, University of Naples "Parthenope", Italy.
    15. Ronald Kumar & Madhukar Singh, 2014. "Role of health expenditure and ICT in a small island economy: a study of Fiji," Quality & Quantity: International Journal of Methodology, Springer, vol. 48(4), pages 2295-2311, July.
    16. Alfredo Marvão Pereira & Rui Manuel Pereira & Pedro G. Rodrigues, 2017. "Health Care Investments and Economic Performance in Portugal: An Industry Level Analysis," GEE Papers 0083, Gabinete de Estratégia e Estudos, Ministério da Economia, revised Nov 2017.
    17. Lago-Peñas, Santiago & Cantarero-Prieto, David & Blázquez-Fernández, Carla, 2013. "On the relationship between GDP and health care expenditure: A new look," Economic Modelling, Elsevier, vol. 32(C), pages 124-129.
    18. Getzen, Thomas E., 2000. "Health care is an individual necessity and a national luxury: applying multilevel decision models to the analysis of health care expenditures," Journal of Health Economics, Elsevier, vol. 19(2), pages 259-270, March.
    19. Thompson, Kristina & Ophem, Johan van & Wagemakers, Annemarie, 2019. "Studying the impact of the Eurozone’s Great Recession on health: Methodological choices and challenges," Economics & Human Biology, Elsevier, vol. 35(C), pages 162-184.
    20. Jiang, Yunyun & Zhao, Tianhao & Zheng, Haitao, 2021. "Population aging and its effects on the gap of urban public health insurance in China," China Economic Review, Elsevier, vol. 68(C).
    21. Xiaocang Xu & Haoran Yang & Chang Li, 2022. "Theoretical Model and Actual Characteristics of Air Pollution Affecting Health Cost: A Review," IJERPH, MDPI, vol. 19(6), pages 1-14, March.
    22. Mihaela TOMAZIU-TODOSIA & Iuliana- Claudia MIHALACHE & Felicia- Cătălina APETROI (RĂCOARE), 2020. "Financial resources - an important aspect of increasing the performance of the health care sector in Romania," CES Working Papers, Centre for European Studies, Alexandru Ioan Cuza University, vol. 12(1), pages 89-99, May.
    23. Katharina Schley, 2018. "Health care service provision in Europe and regional diversity: a stochastic metafrontier approach," Health Economics Review, Springer, vol. 8(1), pages 1-11, December.
    24. Jennifer Roberts, 1999. "Sensitivity of elasticity estimates for OECD health care spending: analysis of a dynamic heterogeneous data field," Health Economics, John Wiley & Sons, Ltd., vol. 8(5), pages 459-472, August.
    25. Yan Feng & Toby Watt & Anita Charlesworth & Grace Marsden & Adam Roberts & Jon Sussex, 2017. "What Determines the Health Care Expenditure of High Income Countries? A Dynamic Estimation," Applied Economics and Finance, Redfame publishing, vol. 4(6), pages 1-16, November.
    26. Wei-Bin Zhang, 2018. "Dynamic Interactions Between Health, Human Capital and Wealth," Academicus International Scientific Journal, Entrepreneurship Training Center Albania, issue 17, pages 122-145, March.
    27. Tamara Fioroni, 2010. "Optimal savings and health spending over the life cycle," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(4), pages 355-365, August.
    28. Potrafke, Niklas, 2010. "The growth of public health expenditures in OECD countries: Do government ideology and electoral motives matter?," Munich Reprints in Economics 19280, University of Munich, Department of Economics.
    29. Wei-Bin Zhang, 2018. "Economic Growth and Health Dynamics with Government Subsidies for Healthcare," Acta Oeconomica Pragensia, Prague University of Economics and Business, vol. 2018(3), pages 3-23.
    30. Costa-i-Font, Joan & Gemmill, Marin & Rubert, Gloria, 2009. "Re-visiting the health care luxury good hypothesis: aggregation, precision, and publication biases?," LSE Research Online Documents on Economics 25303, London School of Economics and Political Science, LSE Library.
    31. Hartwig, Jochen, 2008. "What drives health care expenditure?--Baumol's model of 'unbalanced growth' revisited," Journal of Health Economics, Elsevier, vol. 27(3), pages 603-623, May.
    32. Abbas, Faisal & Hiemenz, Ulrich, 2011. "Determinants of Public Health expenditures in Pakistan," Discussion Papers 118422, University of Bonn, Center for Development Research (ZEF).
    33. Monica Auteri & Mauro Costantini, 2004. "Is social protection a necessity or a luxury good? New multivariate cointegration panel data results," Applied Economics, Taylor & Francis Journals, vol. 36(17), pages 1887-1898.
    34. Livio Di Matteo, 2010. "The sustainability of public health expenditures: evidence from the Canadian federation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(6), pages 569-584, December.
    35. Wei-Bin Zhang, 2018. "Health, Environment, and Wealth," Izvestia Journal of the Union of Scientists - Varna. Economic Sciences Series, Union of Scientists - Varna, Economic Sciences Section, vol. 7(3), pages 109-123, December.
    36. Seher Sülkü & Asena Caner, 2011. "Health care expenditures and gross domestic product: the Turkish case," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(1), pages 29-38, February.
    37. MEZEI Sebastian & PENTESCU Alma, 2022. "Underfunding Of The Health System In Romania," Revista Economica, Lucian Blaga University of Sibiu, Faculty of Economic Sciences, vol. 74(3), pages 71-81, October.
    38. Marc Saez & Carles Murillo, 1994. "Shared ‘features’ in prices: Income and price elasticities for health care expenditures," Health Economics, John Wiley & Sons, Ltd., vol. 3(4), pages 267-279, July.
    39. Mahmoud sabra, 2022. "Health expenditure, life expectancy, fertility rate, CO2 emissions and economic growth Do public, private and external health expenditure matter," International Journal of Economic Sciences, European Research Center, vol. 11(2), pages 179-191, November.
    40. Eriksen, Steffen & Wiese, Rasmus, 2019. "Policy induced increases in private healthcare financing provide short-term relief of total healthcare expenditure growth: Evidence from OECD countries," European Journal of Political Economy, Elsevier, vol. 59(C), pages 71-82.
    41. Saten Kumar, 2013. "Systems GMM estimates of the health care spending and GDP relationship: a note," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(3), pages 503-506, June.
    42. Allen C. Goodman & Miron Stano & John M. Tilford, 1999. "Household Production of Health Investment: Analysis and Applications," Southern Economic Journal, John Wiley & Sons, vol. 65(4), pages 791-806, April.
    43. Jay Pan & Gordon G. Liu, 2012. "The Determinants Of Chinese Provincial Government Health Expenditures: Evidence From 2002–2006 Data," Health Economics, John Wiley & Sons, Ltd., vol. 21(7), pages 757-777, July.
    44. Di Matteo, Livio, 2000. "The determinants of the public-private mix in Canadian health care expenditures: 1975-1996," Health Policy, Elsevier, vol. 52(2), pages 87-112, June.
    45. Mark Berger & Jodi Messer, 2002. "Public financing of health expenditures, insurance, and health outcomes," Applied Economics, Taylor & Francis Journals, vol. 34(17), pages 2105-2113.
    46. Carlos Murillo & Cyrille Piatecki & Marc Saez, 1993. "Health care expenditure and income in Europe," Health Economics, John Wiley & Sons, Ltd., vol. 2(2), pages 127-138, July.
    47. Clemente, Jesús & Lazaro, Angelina & Montanes, Antonio, 2016. "Public health expenditure in Spain: is there partisan behaviour?," MPRA Paper 69781, University Library of Munich, Germany.
    48. Samia Nasreen, 2021. "Association between health expenditures, economic growth and environmental pollution: Long‐run and causality analysis from Asian economies," International Journal of Health Planning and Management, Wiley Blackwell, vol. 36(3), pages 925-944, May.
    49. Joan Costa-Font & Francesco Moscone, 2008. "The impact of decentralization and inter-territorial interactions on Spanish health expenditure," Empirical Economics, Springer, vol. 34(1), pages 167-184, February.
    50. Moheddine Younsi & Mohamed Chakroun & Amine Nafla, 2016. "Robust analysis of the determinants of healthcare expenditure growth: evidence from panel data for low-, middle- and high-income countries," International Journal of Health Planning and Management, Wiley Blackwell, vol. 31(4), pages 580-601, October.
    51. Joan Costa‐Font & Marin Gemmill & Gloria Rubert, 2011. "Biases in the healthcare luxury good hypothesis?: a meta‐regression analysis," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 174(1), pages 95-107, January.
    52. David Tordrup & Aris Angelis & Panos Kanavos, 2013. "Preferences on Policy Options for Ensuring the Financial Sustainability of Health Care Services in the Future: Results of a Stakeholder Survey," Applied Health Economics and Health Policy, Springer, vol. 11(6), pages 639-652, December.
    53. Isabel Casas & Jiti Gao & Bin Peng & Shangyu Xie, 2019. "Time-Varying Income Elasticities of Healthcare Expenditure for the OECD and Eurozone," Monash Econometrics and Business Statistics Working Papers 28/19, Monash University, Department of Econometrics and Business Statistics.
    54. Tiffany Hui-Kuang Yu & Hong Yih Chu, 2007. "Is health care really a luxury? A demand and supply approach," Applied Economics, Taylor & Francis Journals, vol. 39(9), pages 1127-1131.
    55. Joan Costa‐Font & Jordi Pons‐Novell, 2007. "Public health expenditure and spatial interactions in a decentralized national health system," Health Economics, John Wiley & Sons, Ltd., vol. 16(3), pages 291-306, March.
    56. Marwa Farag & A. NandaKumar & Stanley Wallack & Dominic Hodgkin & Gary Gaumer & Can Erbil, 2012. "The income elasticity of health care spending in developing and developed countries," International Journal of Health Economics and Management, Springer, vol. 12(2), pages 145-162, June.
    57. Potrafke, Niklas, 2009. "Political cycles and economic performance in OECD countries: empirical evidence from 1951-2006," MPRA Paper 23751, University Library of Munich, Germany.
    58. Frank Denton & Dean Mountain, 2014. "The implications of mean scaling for the calculation of aggregate consumer elasticities," The Journal of Economic Inequality, Springer;Society for the Study of Economic Inequality, vol. 12(3), pages 297-314, September.
    59. Mehdi Barati & Hadiseh Fariditavana, 2020. "Asymmetric effect of income on the US healthcare expenditure: evidence from the nonlinear autoregressive distributed lag (ARDL) approach," Empirical Economics, Springer, vol. 58(4), pages 1979-2008, April.
    60. Younsi, Moheddine & Bechtini, Marwa, 2020. "Développement de l'assurance, dépenses de santé et croissance économique dans les pays de l'OCDE: Nouvelle approche de causalité en panel [Insurance Development, Health Expenditure and Economic Gro," MPRA Paper 99091, University Library of Munich, Germany.
    61. Till Bärnighausen & David Bloom, 2009. "Changing Research Perspectives on the Global Health Workforce," PGDA Working Papers 4609, Program on the Global Demography of Aging.
    62. Panos Kanavos & Olivier Wouters & Aris Angelis & David Tordrup & Panos Kanavos, 2017. "Is the Funding of Public National Health Systems Sustainable over the Long Term? Evidence from Eight OECD Countries," Global Policy, London School of Economics and Political Science, vol. 8(s2), pages 7-22, March.
    63. Mahlich Jörg & Sindern Jörn & Suppliet Moritz, 2015. "Vergleichbarkeit internationaler Arzneimittelpreise," Perspektiven der Wirtschaftspolitik, De Gruyter, vol. 16(2), pages 164-172, June.
    64. Berta Rivera & Luis Currais, 2003. "The effect of health investment on growth: A causality analysis," International Advances in Economic Research, Springer;International Atlantic Economic Society, vol. 9(4), pages 312-323, November.
    65. Héctor Bellido & Lorena Olmos & Juan Antonio Román-Aso, 2019. "Do political factors influence public health expenditures? Evidence pre- and post-great recession," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 455-474, April.
    66. Paresh Kumar Narayan, 2010. "Modelling health and output at business cycle horizons for the USA," Health Economics, John Wiley & Sons, Ltd., vol. 19(7), pages 872-880, July.
    67. James Ang, 2010. "The determinants of health care expenditure in Australia," Applied Economics Letters, Taylor & Francis Journals, vol. 17(7), pages 639-644.
    68. Masayoshi Hayashi & Akiko Oyama, 2014. "Factor decomposition of inter-prefectural health care expenditure disparities in Japan," Discussion papers ron264, Policy Research Institute, Ministry of Finance Japan.
    69. AMBA OYON, Claude Marius & Mbratana, Taoufiki, 2017. "Simultaneous equation models with spatially autocorrelated error components," MPRA Paper 82395, University Library of Munich, Germany.
    70. Tang, Chor Foon, 2010. "Revisiting the health-income nexus in Malaysia: ARDL cointegration and Rao's F-test for causality," MPRA Paper 27287, University Library of Munich, Germany.
    71. Joan Gil & Eduard Gracia, 2002. "A comparison of the USA health care effort with other OECD countries," Hacienda Pública Española / Review of Public Economics, IEF, vol. 161(2), pages 31-48, June.
    72. Robert S. Woodward & Le Wang, 2012. "The Oh‐So Straight And Narrow Path: Can The Health Care Expenditure Curve Be Bent?," Health Economics, John Wiley & Sons, Ltd., vol. 21(8), pages 1023-1029, August.
    73. Herwartz, Helmut & Theilen, Bernd, 2000. "The determinants of health care expenditure: Testing pooling restrictions in small samples," SFB 373 Discussion Papers 2000,78, Humboldt University of Berlin, Interdisciplinary Research Project 373: Quantification and Simulation of Economic Processes.
    74. Hansen, Paul & King, Alan, 1996. "The determinants of health care expenditure: A cointegration approach," Journal of Health Economics, Elsevier, vol. 15(1), pages 127-137, February.
    75. Carla Blazquez-Fernandez & David Cantarero & Patricio Perez, 2014. "Disentangling the heterogeneous income elasticity and dynamics of health expenditure," Applied Economics, Taylor & Francis Journals, vol. 46(16), pages 1839-1854, June.
    76. Erkan Erdil & I. Hakan Yetkiner, 2009. "The Granger-causality between health care expenditure and output: a panel data approach," Applied Economics, Taylor & Francis Journals, vol. 41(4), pages 511-518.
    77. Y. Natalia Alfonso & Guiru Ding & David Bishai, 2016. "Income Elasticity of Vaccines Spending versus General Healthcare Spending," Health Economics, John Wiley & Sons, Ltd., vol. 25(7), pages 860-872, July.
    78. Ousmane Traoré, 2020. "Economic Growth and Human Capital Accumulation across Countries: Evidence from WAEMU Region," International Advances in Economic Research, Springer;International Atlantic Economic Society, vol. 26(2), pages 147-159, May.
    79. Yuping Tsai, 2018. "Social Security Income and Health Care Spending: Evidence from the Social Security Notch," Scandinavian Journal of Economics, Wiley Blackwell, vol. 120(2), pages 440-464, April.
    80. Ben Brewer & Karen Smith Conway & Deniz Ozabaci & Robert S. Woodward, 2022. "US Health Care Expenditures, GDP and Health Policy Reforms: Evidence from End-of-Sample Structural Break Tests," Eastern Economic Journal, Palgrave Macmillan;Eastern Economic Association, vol. 48(4), pages 451-487, October.
    81. Pierella Paci & Adam Wagstaff, 1993. "Equity and efficiency in Italian health care," Health Economics, John Wiley & Sons, Ltd., vol. 2(1), pages 15-29, April.
    82. Ali Akbar Fazaeli & Hossein Ghaderi & Masoud Salehi & Ali Reza Fazaeli, 2016. "Health Care Expenditure and GDP in Oil Exporting Countries: Evidence From OPEC Data, 1995-2012," Global Journal of Health Science, Canadian Center of Science and Education, vol. 8(2), pages 1-93, February.
    83. Paresh Kumar Narayan, 2007. "Do health expenditures ‘catch‐up’? Evidence from OECD countries," Health Economics, John Wiley & Sons, Ltd., vol. 16(10), pages 993-1008, October.
    84. Roger D. Congleton & Alberto Batinti & Rinaldo Pietratonio, 2017. "The Electoral Politics and the Evolution of Complex Healthcare Systems," Kyklos, Wiley Blackwell, vol. 70(4), pages 483-510, November.
    85. Son Hong Nghiem & Luke Brian Connelly, 2017. "Convergence and determinants of health expenditures in OECD countries," Health Economics Review, Springer, vol. 7(1), pages 1-11, December.
    86. Pierre‐Yves Crémieux & Pierre Ouellette & Caroline Pilon, 1999. "Health care spending as determinants of health outcomes," Health Economics, John Wiley & Sons, Ltd., vol. 8(7), pages 627-639, November.
    87. Benoit Dervaux & Gary Ferrier & Herve Leleu & Vivian Valdmanis, 2004. "Comparing French and US hospital technologies: a directional input distance function approach," Applied Economics, Taylor & Francis Journals, vol. 36(10), pages 1065-1081.
    88. Tang, Chor Foon, 2010. "The determinants of health expenditure in Malaysia: A time series analysis," MPRA Paper 24356, University Library of Munich, Germany.
    89. Lacheheb, Miloud & Med Nor, Norashidah & Baloch, Imdadullah, 2014. "Health Expenditure, education and Economic Growth in MENA Countries," MPRA Paper 60388, University Library of Munich, Germany.
    90. Di Matteo, Livio & Cantarero-Prieto, David, 2018. "The Determinants of Public Health Expenditures: Comparing Canada and Spain," MPRA Paper 87800, University Library of Munich, Germany.
    91. DO ANGO, Simplicio & AMBA OYON, Claude Marius, 2016. "Health expenditure and Real disposable Income in the ECCAS: A Causal Study using spatial panel approach," MPRA Paper 79684, University Library of Munich, Germany.
    92. Andree Ehlert & Dirk Oberschachtsiek, 2014. "Does managed care reduce health care expenditure? Evidence from spatial panel data," International Journal of Health Economics and Management, Springer, vol. 14(3), pages 207-227, September.
    93. Gyimah-Brempong, Kwabena & Wilson, Mark, 2004. "Health human capital and economic growth in Sub-Saharan African and OECD countries," The Quarterly Review of Economics and Finance, Elsevier, vol. 44(2), pages 296-320, May.
    94. Dubey, Jay Dev, 2020. "Income elasticity of demand for health care and it's change over time: Across the income groups and levels of health expenditure in India," Working Papers 20/324, National Institute of Public Finance and Policy.
    95. Pierre‐Yves Crémieux & Marie‐Claude Meilleur & Pierre Ouellette & Patrick Petit & Martin Zelder & Ken Potvin, 2005. "Public and private pharmaceutical spending as determinants of health outcomes in Canada," Health Economics, John Wiley & Sons, Ltd., vol. 14(2), pages 107-116, February.
    96. Tsung-Yu Hsieh & Huai-I Lee & Yu-Ju Huang, 2016. "An investigation of the factors affecting medical expenses: The case of Taiwan’s NHI implementation," Journal of Applied Finance & Banking, SCIENPRESS Ltd, vol. 6(6), pages 1-8.
    97. Faisal Abbas & Ulrich Hiemenz, 2013. "What determines public health expenditures in Pakistan? Role of income, urbanization and unemployment," Economic Change and Restructuring, Springer, vol. 46(4), pages 341-362, November.
    98. Anindya Sen, 2005. "Is Health Care a Luxury? New Evidence from OECD Data," International Journal of Health Economics and Management, Springer, vol. 5(2), pages 147-164, June.
    99. Tang, Chor Foon, 2011. "Multivariate Granger Causality and the Dynamic Relationship between Health Care Spending, Income and Relative Price of Health Care in Malaysia," Hitotsubashi Journal of Economics, Hitotsubashi University, vol. 52(2), pages 199-214, December.
    100. Currais, Luis, 2000. "Population, Growth and Health Expenditure," Revista Brasileira de Economia - RBE, EPGE Brazilian School of Economics and Finance - FGV EPGE (Brazil), vol. 54(4), October.
    101. Di Matteo, Livio, 2005. "The macro determinants of health expenditure in the United States and Canada: assessing the impact of income, age distribution and time," Health Policy, Elsevier, vol. 71(1), pages 23-42, January.
    102. Mujaheed Shaikh & Afschin Gandjour, 2019. "Pharmaceutical expenditure and gross domestic product: Evidence of simultaneous effects using a two‐step instrumental variables strategy," Health Economics, John Wiley & Sons, Ltd., vol. 28(1), pages 101-122, January.
    103. Vitor Castro, 2017. "Pure, White and Deadly… Expensive: A Bitter Sweetness in Health Care Expenditure," Health Economics, John Wiley & Sons, Ltd., vol. 26(12), pages 1644-1666, December.
    104. McCoskey, Suzanne K. & Selden, Thomas M., 1998. "Health care expenditures and GDP: panel data unit root test results," Journal of Health Economics, Elsevier, vol. 17(3), pages 369-376, June.
    105. Sung-Ha HwangBy & Jungmin Lee, 2017. "Conspicuous consumption and income inequality," Oxford Economic Papers, Oxford University Press, vol. 69(4), pages 870-896.
    106. Murthy, Vasudeva N.R. & Okunade, Albert A., 2016. "Determinants of U.S. health expenditure: Evidence from autoregressive distributed lag (ARDL) approach to cointegration," Economic Modelling, Elsevier, vol. 59(C), pages 67-73.
    107. Shuyun May Li & Solmaz Moslehi & Siew Ling Yew, 2012. "Public-Private Mix of Health Expenditure: A Political Economy Approach and A Quantitative Exercise," Monash Economics Working Papers 11-12, Monash University, Department of Economics.
    108. Okunade, Albert A. & Suraratdecha, Chutima, 2006. "The pervasiveness of pharmaceutical expenditure inertia in the OECD countries," Social Science & Medicine, Elsevier, vol. 63(1), pages 225-238, July.
    109. Jonas Schreyögg & Oliver Tiemann & Tom Stargardt & Reinhard Busse, 2008. "Cross‐country comparisons of costs: the use of episode‐specific transitive purchasing power parities with standardised cost categories," Health Economics, John Wiley & Sons, Ltd., vol. 17(S1), pages 95-103, January.
    110. Christine Huttin, 2000. "A cluster analysis on income elasticity variations and US pharmaceutical expenditures," Applied Economics, Taylor & Francis Journals, vol. 32(10), pages 1241-1247.
    111. Jay Dev Dubey, 2021. "Measuring Income Elasticity of Healthcare-Seeking Behavior in India: A Conditional Quantile Regression Approach," Journal of Quantitative Economics, Springer;The Indian Econometric Society (TIES), vol. 19(4), pages 767-793, December.
    112. Muhammad Usman & Zhiqiang Ma & Muhammad Wasif Zafar & Abdul Haseeb & Rana Umair Ashraf, 2019. "Are Air Pollution, Economic and Non-Economic Factors Associated with Per Capita Health Expenditures? Evidence from Emerging Economies," IJERPH, MDPI, vol. 16(11), pages 1-22, June.
    113. Joan M. O'Connell, 1996. "The relationship between health expenditures and the age structure of the population in OECD countries," Health Economics, John Wiley & Sons, Ltd., vol. 5(6), pages 573-578, November.
    114. Iuliana-Claudia Mihalache & Felicia-Cä‚Tä‚Lina Apetroi (Rä‚Coare), 2020. "The Evolution Of The Financing Of Health Services In Romania, From The Semashko Model To The Bismarck Model," Review of Economic and Business Studies, Alexandru Ioan Cuza University, Faculty of Economics and Business Administration, issue 25, pages 137-147, June.
    115. Joseph P. Newhouse, 1992. "Medical Care Costs: How Much Welfare Loss?," Journal of Economic Perspectives, American Economic Association, vol. 6(3), pages 3-21, Summer.
    116. Di Matteo, Livio, 2014. "Physician numbers as a driver of provincial government health spending in Canadian health policy," Health Policy, Elsevier, vol. 115(1), pages 18-35.
    117. Mahmoud M. SABRA, 2022. "Health expenditure, life expectancy, fertility rate, CO2 emissions and economic growth Do public, private and external health expenditure matter?," Theoretical and Applied Economics, Asociatia Generala a Economistilor din Romania - AGER, vol. 0(3(632), A), pages 89-102, Autumn.
    118. Amiri, Arshia & Ventelou, Bruno, 2012. "Granger causality between total expenditure on health and GDP in OECD: Evidence from the Toda–Yamamoto approach," Economics Letters, Elsevier, vol. 116(3), pages 541-544.
    119. Chakroun, Mohamed, 2009. "Health care expenditure and GDP: An international panel smooth transition approach," MPRA Paper 14322, University Library of Munich, Germany.
    120. Joao Ricardo Faria & Miguel Leon-Ledesma & Adolfo Sachsida, 2006. "Population and income: Is there a puzzle?," Journal of Development Studies, Taylor & Francis Journals, vol. 42(6), pages 909-917.
    121. Po-Chin Wu & Shiao-Yen Liu & Sheng-Chieh Pan, 2014. "Does Misery Index Matter for the Persistence of Health Spending? Evidence from OECD Countries," Social Indicators Research: An International and Interdisciplinary Journal for Quality-of-Life Measurement, Springer, vol. 118(2), pages 893-910, September.
    122. Wang, Kuan-Min, 2011. "Health care expenditure and economic growth: Quantile panel-type analysis," Economic Modelling, Elsevier, vol. 28(4), pages 1536-1549, July.
    123. Sarah Wordsworth & Anne Ludbrook, 2005. "Comparing costing results in across country economic evaluations: the use of technology specific purchasing power parities," Health Economics, John Wiley & Sons, Ltd., vol. 14(1), pages 93-99, January.
    124. Muhammad Arshad Khan & Muhammad Iftikhar Ul Husnain, 2019. "Is health care a luxury or necessity good? Evidence from Asian countries," International Journal of Health Economics and Management, Springer, vol. 19(2), pages 213-233, June.
    125. Erkan Erdil & I. Hakan Yetkiner, 2004. "A Panel Data Approach for Income-Health Causality," Working Papers FNU-47, Research unit Sustainability and Global Change, Hamburg University, revised Apr 2004.
    126. Münch Angela & Fielding David & Freytag Andreas, 2020. "Public Spending on Health as Political Instrument? – Regime-type dependency of public spending," Open Economics, De Gruyter, vol. 3(1), pages 121-134, January.
    127. Marias H. Gestsson & Gylfi Zoega, 2014. "A Golden Rule of Health Care," Birkbeck Working Papers in Economics and Finance 1412, Birkbeck, Department of Economics, Mathematics & Statistics.
    128. Michael C. M. Leung & Yong Wang, 2010. "Endogenous Health Care, Life Expectancy And Economic Growth," Pacific Economic Review, Wiley Blackwell, vol. 15(1), pages 11-31, February.
    129. Kwame Acheampong, 2019. "The interaction effect of foreign capital inflows and financial development on economic welfare in sub-Saharan Africa," Financial Innovation, Springer;Southwestern University of Finance and Economics, vol. 5(1), pages 1-33, December.
    130. Slade, Eric P. & Anderson, Gerard F., 2001. "The relationship between per capita income and diffusion of medical technologies," Health Policy, Elsevier, vol. 58(1), pages 1-14, October.
    131. Manuel Gómez, 2001. "Subsidy policies in a fertility choice model," Atlantic Economic Journal, Springer;International Atlantic Economic Society, vol. 29(4), pages 438-449, December.
    132. Theo Hitiris, "undated". "Growth and Containment of Health Care Expenditure in Industrial Countries," Discussion Papers 99/15, Department of Economics, University of York.
    133. Blomqvist, A. G. & Carter, R. A. L., 1997. "Is health care really a luxury?," Journal of Health Economics, Elsevier, vol. 16(2), pages 207-229, April.
    134. Di Matteo, Livio & Di Matteo, Rosanna, 1998. "Evidence on the determinants of Canadian provincial government health expenditures: 1965-1991," Journal of Health Economics, Elsevier, vol. 17(2), pages 211-228, April.
    135. Nyman, John A., 1999. "The economics of moral hazard revisited," Journal of Health Economics, Elsevier, vol. 18(6), pages 811-824, December.

  23. Yule, Brian & Parkin, David, 1985. "The demand for dental care: An assessment," Social Science & Medicine, Elsevier, vol. 21(7), pages 753-760, January.

    Cited by:

    1. Harri Sintonen & Timo Maljanen, 1995. "Explaining the utilisation of dental care. Experiences from the finnish dental market," Health Economics, John Wiley & Sons, Ltd., vol. 4(6), pages 453-466, November.
    2. Terance J. Rephann & Tanya Wanchek, 2012. "Filling the Gaps: Dentist Disparities along the Rural Urban Continuum," Working Papers 2012-02, Center for Economic and Policy Studies.
    3. Anna-Lena Trescher & Stefan Listl & Onno Galien & Frank Gabel & Olivier Kalmus, 2020. "Once bitten, twice shy? Lessons learned from an experiment to liberalize price regulations for dental care," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(3), pages 425-436, April.
    4. Lien Nguyen & Unto Häkkinen & Matti Knuuttila & Marjo‐Riitta Järvelin, 2008. "Should we brush twice a day? Determinants of dental health among young adults in Finland," Health Economics, John Wiley & Sons, Ltd., vol. 17(2), pages 267-286, February.

Books

  1. Wren, Maev-Ann & Gillespie, Paddy & Smith, Samantha & Kearns, Karen & Crichton,Siobhan & Parkin, David & Hickey, Anne & Horgan, Frances & Wiley, Miriam, 2014. "Towards Earlier Discharge, Better Outcomes, Lower Cost: Stroke Rehabilitation in Ireland," Research Series, Economic and Social Research Institute (ESRI), number BKMNEXT277, June.

    Cited by:

    1. Walsh, Brendan & Wren, Maev-Ann & Smith, Samantha & Lyons, Seán & Eighan, James & Morgenroth, Edgar, 2019. "An analysis of the effects on Irish hospital care of the supply of care inside and outside the hospital," Research Series, Economic and Social Research Institute (ESRI), number RS91, June.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.